US6109269A - Method of treating addiction by brain infusion - Google Patents

Method of treating addiction by brain infusion Download PDF

Info

Publication number
US6109269A
US6109269A US09/303,182 US30318299A US6109269A US 6109269 A US6109269 A US 6109269A US 30318299 A US30318299 A US 30318299A US 6109269 A US6109269 A US 6109269A
Authority
US
United States
Prior art keywords
stimulation
drugs
catheter
signal generator
nucleus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US09/303,182
Inventor
Mark T. Rise
Nina Graves
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medtronic Inc
Original Assignee
Medtronic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medtronic Inc filed Critical Medtronic Inc
Priority to US09/303,182 priority Critical patent/US6109269A/en
Assigned to MEDTRONIC, INC reassignment MEDTRONIC, INC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GRAVES, NINA, RISE, MARK T.
Application granted granted Critical
Publication of US6109269A publication Critical patent/US6109269A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
    • A61M5/172—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic
    • A61M5/1723—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic using feedback of body parameters, e.g. blood-sugar, pressure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/3605—Implantable neurostimulators for stimulating central or peripheral nerve system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00—Anatomical parts of the body
    • A61M2210/06—Head
    • A61M2210/0693—Brain, cerebrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142—Pressure infusion, e.g. using pumps
    • A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
    • A61M5/14276—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body specially adapted for implantation

Definitions

  • opiates such as heroin, opium and morphine
  • the sympathomimetics including cocaine and amphetamines
  • the sedative-hypnotics including alcohol, benzodiazepines and barbiturates and nicotine which has effects similar to opiods and sympathomimetics.
  • Drug dependence is contrasted with drug abuse by the hallmark symptoms of addiction. Drug addiction is characterized by two features, a craving or compulsion to take the drug and an inability to limit intake of the drug. Additionally, drug dependence is associated with tolerance, which is the loss of effect of the drug with repeated administration and withdrawal, defined as the appearance of physical and behavioral symptoms when the drug is not consumed following chronic use.
  • the opponent-process theory describes a process of decreasing positive reward because of increasing tolerance to the consumption of the addicting substance coupled with an increasing negative reinforcement due to withdrawal.
  • the negative reinforcement associated with withdrawal is a motivating factor for continuing consumption of the addicting substance.
  • Certain pharmaceutical agents have been administered to affect the addictive process. Mayer et. al (U.S. Pat. No. 5,556,838) teaches the use of nontoxic NMDA blocking agents coadministered with an addicting substance to prevent the development of tolerance or withdrawal symptoms. The agents are administered acutely through an oral, intravenous, intrathecal, epidural, or intraventricular route. Rose and Levin (U.S. Pat. No. 5,574,052) teaches coadministration of the addictive substance with an antagonist to partially block the pharmacological effects of the substance. The preferred mode of delivery is a transcutaneous patch. Mendelson and Mello propose use of a mixed opiate agonist/antagonist to treat cocaine and opiate addiction. Downs (U.S. Pat. No.
  • Imperato and Romer U.S. Pat. Nos. 5,039,680 and 5,198,459 teach the use of a serotonin antagonist as a treatment for chemical addiction.
  • Nestler et. al. teach the infusion of the growth factors BDNF or NT-4 to inhibit or reverse the neurological adaptive changes that correlate with the behavioral changes of an addictive disorder.
  • Yolles teaches delivery of drugs to treat addictions by eluting them from a polymeric material preferably implanted under the skin. (Curt he does describe lining a catheter or injecting into blood stream--can I focus on the subcutaneous application???)
  • a preferred form of the invention uses one or more drugs and/or electrical stimulation to treat addictions.
  • the treatment is carried out by an implantable pump and a catheter having a proximal end coupled to the pump and having a discharge portion for infusing therapeutic dosages of the one or more drugs into a predetermined infusion site in brain tissue.
  • the treatment may be carried out by an implantable signal generator and an implantable electrode having a proximal end coupled to the signal generator and having a stimulation portion for electrically stimulating a predetermined stimulation site in the brain tissue.
  • treatment is carried out by a combined infusion of therapeutic dosages of the one or more drugs and electrical stimulation of a predetermined stimulation sited in the brain tissue.
  • addiction and impulse control disorders can be controlled to a degree unattainable by prior art methods or apparatus.
  • FIG. 1 is a diagrammatic illustration of a combined catheter and electrode implanted in a brain according to a preferred embodiment of the present invention, and a signal generator and pump coupled to the combined catheter and electrode;
  • FIG. 2 is a cross-sectional view of the catheter-electrode of FIG. 1 taken along line 2--2 of FIG. 3;
  • FIG. 3 is a diagrammatic view of the catheter-electrode shown in FIG. 1;
  • FIG. 4 is a diagrammatic illustration of a catheter and a sensor implanted in a brain and a pump coupled to the catheter and sensor;
  • FIG. 5 is a diagrammatic illustration of a lead and a sensor implanted in a brain and a signal generator coupled to the lead and sensor;
  • FIG. 6 is a diagrammatic illustration of a combined lead and catheter and a sensor implanted in a brain and a signal generator and pump coupled to the combined catheter and electrode and sensor;
  • FIG. 7 is a diagrammatic illustration of a separate lead and catheter and a sensor implanted in a brain and a signal generator and pump coupled to the lead, catheter and sensor;
  • FIG. 8 is a schematic block diagram of a sensor and analog to digital converter circuit used in the preferred embodiment of the invention.
  • FIG. 9 is a flow chart illustrating a preferred form of a microprocessor program for utilizing the sensor to control drug dosage administered to the brain;
  • FIG. 10 is a schematic block diagram of a microprocessor and related circuitry for utilizing the sensor to control stimulation administered to the brain;
  • FIGS. 11-15 are flow charts illustrating a preferred form of microprocessor program for generating stimulation pulses to be administered to the brain
  • FIGS. 16A-16C are timing diagrams showing the relationship between the administration of drugs and electrical stimulation to nerve tissue.
  • FIGS. 17-21 are diagrammatical views of the catheter-electrode shown in FIG. 1 arranged adjacent various types of neural tissue.
  • a pump or device 10 made in accordance with the preferred embodiment may be implanted below the skin of a patient.
  • the device has a port 14 into which a hypodermic needle can be inserted through the skin to inject a quantity of a liquid agent, such as a medication or drug.
  • the liquid agent is delivered from device 10 through a catheter port 20 into a catheter 22.
  • Catheter 22 is positioned to deliver the agent to specific infusion sites in a brain (B).
  • Device 10 may take the form of the like-numbered device shown in U.S. Pat. No. 4,692,147 (Duggan) ("the '147 Patent"), assigned to Medtronic, Inc., Minneapolis, Minn., which is incorporated by reference.
  • An embodiment of pump 10 may be found in the SynchromedTM Infusion System manufactured by Medtronic, Inc. of Minneapolis, Minn. However, pump 10 may take the form of any device used for moving fluid from a reservoir.
  • the distal end of catheter 22 terminates in a cylindrical hollow tube 22A having a distal end 25 implanted into a portion of the brain by conventional stereotactic surgical techniques.
  • a semispherical portion 23 (FIG. 3) at the distal end 25 of tube 22A provides a rounded profile for minimizing tissue disruption during insertion.
  • End 25 is provided with microporous portions 27-29 (FIG. 3) to allow infusion and filtering of a liquid agent.
  • Microporous portions 27-29 are preferably composed of a porous material such as polysulfone hollow fiber, manufactured by Amicon, although polyethylene, polyamides, polypropylene and expanded polytetrafluorethylene (ePTFE) are also suitable.
  • the preferred pore size is approximately less than or equal to 0.22 microns. It is preferred that the maximum pore size be less than or equal to approximately 0.22 microns to prevent any derelict bacterial agents that may be present inside the catheter 22A from entering into the brain B. Furthermore, at larger pore sizes, there is the potential for tissue in-growth that may restrict the flow of agents out of the microporous portions 27-29. Alternatively, end 25 may be provided with multiple holes or slits in which case filtering of the liquid agent may occur within pump 10.
  • Catheter 22 could take the form of a lead catheter combination developed for use outside of the dural covering of the spinal cord to treat pain which is shown in FIG. 1 in U.S. Pat. No. 5,423,877 (Mackey) which is incorporated by reference.
  • catheter 22 could take the form depicted in FIGS. 1-4 in U.S. Pat. Nos. 5,119,832 and 5,458,631 (Xavier) which is incorporated by reference also developed for use outside of the dura to treat pain in which the center lumen 34 terminates in a single opening at the distal end 25 of catheter 22A.
  • tube 22A includes an outer cylindrical insulating jacket 30 and an inner cylindrical insulating jacket 32 that defines a cylindrical catheter lumen 34.
  • a multifilar coil of wire 36 is embedded in tube 22A as shown.
  • wire 36 could consist of multifilar stranded wire.
  • the inner cylindrical insulating jacket 32 and outer cylindrical insulating jacket 30 should be sufficiently flexible to facilitate insertion.
  • the outer cylindrical insulating jacket 30 should be biocompatible. While it is desirable to have the inner insulating jacket 32 be biocompatible it may not be absolutely necessary provided the inner insulating layer can be kept from contacting the biological tissue.
  • An enhanced tear resistant silicone elastomer or polyurethane are examples of materials that could be used. A durometer shore value of 80 is preferred.
  • Tube 22A is surgically implanted through a hole in the skull 123 and catheter 22 is implanted between the skull and the scalp 125 as shown in FIG. 1.
  • a stylet may be placed into the center of tube 22A to give it stiffness when introducing the tube into the brain.
  • center lumen 34 constitutes a catheter which can be used to infuse an agent, including a drug.
  • Catheter 22 is joined to implanted device 10 in the manner shown.
  • Tube 22A may be continuous with tube 22 or there may be an interveining connection most likely at the burr hole or located somewhere along the subcutaneous path.
  • Catheter 22 may be divided into twin tubes, tube 22A and a second tube (not shown), that are implanted into the brain bilaterally.
  • the second tube may be supplied with drugs from a separate catheter and pump and with electrodes from a separate signal generator.
  • a system or device 16 made in accordance with the preferred embodiment also may be implanted below the skin of a patient.
  • Device 16 may take the form of a signal generator Model 7424 manufactured by Medtronic, Inc. of Minneapolis, Minn. under the trademark Itrel II.
  • tube 22A terminates in stimulation electrodes 38 and 40 (FIG. 3).
  • Each of electrodes 38 and 40 is individually connected to device 16 through a conductor in wire bundle 36 (FIG. 2).
  • the wires exit catheter 22 to form a cable 42 which is joined to implanted signal generator 16 in the manner shown in FIG. 1. While the preferred embodiment shows two electrodes on tube 22A (FIG. 3), some brain locations may require a greater number.
  • tube 22A may have only one electrode using a portion of the case of the signal generator 16 (FIG. 1) as the reference electrode.
  • infusion conduit 34 (FIG. 2) and conductor conduit 36 may not be concentric tubes but rather separate conduits located beside each other in a common tube as is embodied in FIG. 6 of U.S. Pat. No. 5,458,629 (Baudino et.al.), incorporated by reference.
  • Signal generator 16 is implanted in a human body, preferably in a subcutaneous pocket located over the chest cavity or the abdomen. While showed as separate devices in FIG. 1, devices 10 and 16 could be incorporated into a common device.
  • the present invention may preferably be implemented by providing seven different drug dosages from 0 dosage to a 1.0 ml dosage with 0.1 ml increments between choices.
  • the time interval between dosages can preferably be selected between one and twelve hours in seven choices. This is the same type of dosage and interval described in connection with device 10 shown in the '147 Patent (column 5, beginning at line 63).
  • the seven drug dosages and corresponding time increments may be loaded into RAM 102a (FIG. 11B of the '147 Patent).
  • the selected dosage and interval of a drug is then delivered, as described in the '147 Patent, through catheter 22 and tube 22A to a selected location in the brain appropriate for the treatment of anxiety disorders.
  • the medial-lateral dimensions are relative to midline of the brain; the anterior-posterior dimensions are relative to the midpoint between the anterior commissure and posterior commissure with negative indicating the posterior direction; the dorsal-ventral dimensions are relative to a line connecting the midpoints of the anterior and posterior commissures with negative being ventral to; all dimensions are in centimeters.
  • these agents might be infused into the lateral ventricle or third ventricle of the brain or just beneath the dura above the cortex or in the intrathecal space. In this instance the drug would diffuse to the appropriate site of action.
  • liquid agents which provide the desired actions identified in Table I, ranges of dosages and concentrations for the liquid agents are provided in the following Table III:
  • muM means millimicromolar.
  • Microprocessor 100 within device 10 can be programmed so that a controlled amount of drug described in Table III can be delivered to the specific brain sites described in Table I.
  • both the positive and negative reinforcement of addictive activity can be treated by electrically stimulating brain tissue either alone or while drugs are being administered as described above.
  • the stimulation can be achieved by an ITREL II signal generator implemented as signal generator 16 (FIG. 1).
  • Electrical stimulation of neural tissue may be implemented by providing pulses to electrodes 38 and 40 (FIG. 3) preferably having amplitudes of 0.1 to 20 volts, pulse widths varying from 0.02 to 1.5 milliseconds, and repetition rates preferably varying from 2 to 2500 Hz. Pulses with the selected characteristics are then delivered from signal generator 16 through cable 42, catheter 22, tube 22A and electrodes 38 and 40 to the targeted tissue within brain B. The appropriate stimulation pulses are generated by signal generator 16 based on the programmed values established by the clinician. The type of stimulation administered by signal generator 16 to the brain depends on the specific location at which the electrodes 38 and 40 of tube 22A are surgically implanted and the desired action on the neurons at that location. If the neuronal activity is to be blocked, signal generator 16 will be programmed with a frequency preferably in the range 50 to 2500 HZ. If the neuronal activity is to be facilitated, the stimulus frequency is chosen preferably in the range of 2 to 100 Hz.
  • a microprocessor within signal generator 16 can be programmed so that the desired stimulation can be delivered to the specific brain sites described in Table II.
  • the system shown in FIG. 1 is an open-loop system.
  • the microcomputer algorithm programmed by the clinician sets the stimulation parameters of signal generator 16 and/or infusion rates of infusion pump 10. This algorithm may change the parameter values over time but does so independent of any changes in symptoms the patient may be experiencing.
  • the closed-loop systems show in FIGS. 4-7 which incorporate sensor 130 to provide feedback could be used to provide enhanced results.
  • the device in FIG. 6 allows for the combination of infusion and stimulation both therapies being controlled by a feed back sensor 130.
  • the stimulation electrodes 38 and 40 are made a part of tube 22A as depicted in FIG. 3.
  • the stimulation electrodes 38 and 40 could be located on a separate tube 22B away from the microporous regions 27-29 located on tube 22A. This would allow delivery of stimulation to a different site in brain B than the site where medication is delivered.
  • the sensor 130 is located at still a different site in brain B. Under certain circumstances it may be desirable to have sensor 130 physically located on either tube 22A or tube 22B.
  • a sensor 130 is implanted into a portion of a patient's body suitable for detecting symptoms of the disorder being treated. Sensor 130 is adapted to sense an attribute of the symptom to be controlled or an important related symptom. The positive reinforcing actions of reward are manifest by an increased level of neuronal activity in the Nucleus Accumbens. A preferred embodiment of sensor 130 would sense the increased neuronal activity of the Nucleus Accumbens.
  • Brain EEG (e.g., cortical potentials recorded above the neurons controlling specific aspects of behavior associated with the neurological disorder) also may be detected by sensor 130.
  • sensor 130 would take the form of an electrode with impedence values preferably chosen to optimize recording of electrical signals.
  • sensor 130 would include a device capable of detecting nerve compound action potentials (e.g., neuronal information in pathways of the brain concerned with the neuronal disorder.
  • nerve compound action potentials e.g., neuronal information in pathways of the brain concerned with the neuronal disorder.
  • Sensor 130 also may take the form of a device capable of detecting single nerve cell or axon activity that is related to the pathways at the cause of the symptom, or that reflects sensations which are elicited by the symptom.
  • a sensor may be located deep in the brain.
  • sensor 130 may take the form of an electrode inserted into the internal capsule, cortex or basal ganglia of the brain. Signals of any kind that are received by the sensor may by amplified before transmission to circuitry contained within device 10 or device 16.
  • Sensor 130 may take the form of a transducer consisting of an electrode with an ion selective coating applied which is capable of directly transducing the amount of a particular transmitter substance or its breakdown by-products found in the interstitial space of a region of the brain such as the ventral lateral thalamus.
  • the level of the interstitial transmitter substance is an indicator of the relative activity of the brain region.
  • An example of this type of transducer is described in the paper "Multichannel semiconductor-based electrodes for in vivo electrochemical and electrophysiological studies in rat CNS" by Craig G. van Horne, Spencer Bement, Barry J. Hoffer, and Greg A. Gerhardt, published in Neuroscience Letters, 120 (1990) 249-252.
  • Sensor 130 may be external to the body communicating with the implanted portions through telemetry.
  • the output of sensor 130 is coupled by a cable 132 comprising conductors 134 and 135 to the input of analog to digital converter 140.
  • the output of an external feedback sensor would communicate with the implanted pulse generator or pump through a telemetry downlink.
  • the output of the analog to digital converter is connected to terminals EF2 BAR and EF3 BAR shown in FIG. 11A of U.S. Pat. No. 4,692,147 ("'147 Patent"). Before converter 140 is connected to the terminals, the demodulator 101 currently shown in FIG. 11A would be disconnected.
  • a drug can be delivered essentially continuously (within the constraints of the particular delivery device being used) or it may be delivered during intermittent intervals coordinated to reflect the half-life of the particular agent being infused or with circadian rhythms.
  • the cravings or negative reinforcments may normally subside at night when the person is sleeping so the drug delivery rates might be reduced to coincide with the hours between 10 p.m. and 7 a.m.
  • Microprocessor 100 within device 10 can be programmed so that a controlled amount of drug can be delivered to the specific brain sites described in Table I.
  • sensor 130 can be used with a closed loop feedback system in order to automatically determine the level of drug delivery necessary to alleviate the symptoms of the neurological disorder.
  • the applicants have discovered that the efficacy of treatment may be enhanced if the neural tissue is stimulated while drugs are being administered as described above.
  • the stimulation can be achieved by a modified form of the ITREL II signal generator implemented as signal generator 16 (FIG. 1) which is described in FIG. 10.
  • the output of sensor 130 is coupled by cable 132, comprising conductors 134 and 135, to the input of an analog to digital converter 206.
  • the output of an external sensor would communicate with the implanted pulse generator through a telemetry downlink.
  • the output from sensor 130 can be filtered by an appropriate electronic filter in order to provide a control signal for signal generator 16.
  • An example of such a filter is found in U.S. Pat. No. 5,259,387 "Muscle Artifact Filter, Issued to Victor de Pinto on Nov. 9, 1993.
  • the output of the analog to digital converter 206 is connected to a microprocessor 200 through a peripheral bus 202 including address, data and control lines.
  • Microprocessor 200 processes the sensor data in different ways depending on the type of transducer in use. When the signal on sensor 130 exceeds a level programmed by the clinician and stored in a memory 204, increasing amounts of stimulation will be applied through an output driver 224.
  • the stimulus pulse frequency is controlled by programming a value to a programmable frequency generator 208 using bus 202.
  • the programmable frequency generator provides an interrupt signal to microprocessor 200 through an interrupt line 210 when each stimulus pulse is to be generated.
  • the frequency generator may be implemented by model CDP1878 sold by Harris Corporation.
  • the amplitude for each stimulus pulse is programmed to a digital to analog converter 218 using bus 202.
  • the analog output is conveyed through a conductor 220 to an output driver circuit 224 to control stimulus amplitude.
  • Microprocessor 200 also programs a pulse width control module 214 using bus 202.
  • the pulse width control provides an enabling pulse of duration equal to the pulse width via a conductor. Pulses with the selected characteristics are then delivered from signal generator 16 through cable 22 and lead 22A or 22B to the target locations of a brain B.
  • Microprocessor 200 executes an algorithm shown in FIGS. 11-15 in order to provide stimulation with closed loop feedback control.
  • the clinician programs certain key parameters into the memory of the implanted device via telemetry. These parameters may be updated subsequently as needed.
  • Step 400 in FIG. 11 indicates the process of first choosing whether the neural activity at the stimulation site is to be blocked or facilitated (step 400(1)) and whether the sensor location is one for which an increase in the neural activity at that location is equivalent to an increase in neural activity at the stimulation target or vice versa (step 400(2)).
  • step 400(3) the clinician must program the range of values for pulse width (step 400(3)), amplitude (step 400(4)) and frequency (step 400(5)) which signal generator 16 may use to optimize the therapy.
  • the clinician may also choose the order in which the parameter changes are made (step 400(6)). Alternatively, the clinician may elect to use default values.
  • the algorithm for selecting parameters is different depending on whether the clinician has chosen to block the neural activity at the stimulation target or facilitate the neural activity.
  • FIG. 11 details steps of the algorithm to make parameter changes.
  • the algorithm uses the clinician programmed indication of whether the neurons at the particular location of the stimulating electrode are to be facilitated or blocked in order to decide which path of the parameter selection algorithm to follow (step 420, FIG. 12). If the neuronal activity is to be blocked, signal generator 16 first reads the feedback sensor 130 in step 421. If the sensor values indicate the activity in the neurons is too high (step 422), the algorithm in this embodiment first increases the frequency of stimulation in step 424 provided this increase does not exceed the preset maximum value set by the physician. Step 423 checks for this condition. If the frequency parameter is not at the maximum, the algorithm returns to step 421 through path 421A to monitor the feed back signal from sensor 130.
  • step 426 the algorithm next increases the pulse width in step 426 (FIG. 13), again with the restriction that this parameter has not exceeded the maximum value as checked for in step 425 through path 423A. Not having reached maximum pulse width, the algorithm returns to step 421 to monitor the feedback signal from sensor 130. Should the maximum pulse width have been reached, the algorithm next increases amplitude in a like manner as shown in steps 427 and 428. In the event that all parameters reach the maximum, a notification message is set in step 429 to be sent by telemetry to the clinician indicating that device 16 is unable to reduce neural activity to the desired level.
  • the algorithm would follow a different sequence of events.
  • the frequency parameter would be fixed at a value chosen by the clinician to facilitate neuronal activity in step 430 (FIG. 14) through path 420A.
  • the algorithm uses the values of the feedback sensor to determine if neuronal activity is being adequately controlled. In this case, inadequate control indicates that the neuronal activity of the stimulation target is too low.
  • Neuronal activity is increased by first increasing stimulation amplitude (step 434) provided it doesn't exceed the programmed maximum value checked for in step 433.
  • step 435 and 436 the algorithm increases pulse width to its maximum value in steps 435 and 436 (FIG. 15). A lack of adequate alteration of the symptoms of the neurological disorder, even though maximum parameters are used, is indicated to the clinician in step 437. After steps 434, 436 and 437, the algorithm returns to step 431 through path 431A, and the feedback sensor again is read.
  • steps 410 through 415 constitute the method to do this.
  • a timer is reset in step 415. If there is no need to change any stimulus parameters before the timer has counted out, then it may be possible due to changes in neuronal activity to reduce the parameter values and still maintain appropriate levels of neuronal activity in the target neurons.
  • signal generator 16 tries reducing a parameter in step 413 to determine if control is maintained. If it is, the various parameter values will be ratcheted down until such time as the sensor values again indicate a need to increase them. While the algorithms in FIGS. 11-15 follow the order of parameter selection indicated, other sequences may be programmed by the clinician.
  • FIG. 17 describes one such application in which type A neurons, such as NA, are located in the same region as type B neurons, such as NB which can typically be found in a brain.
  • type A neurons such as NA
  • type B neurons such as NB which can typically be found in a brain.
  • neurons NA can be inhibited or excited with respect to their response to electrical stimulation provided by electrodes 38 and 40, while neurons NB remain unchanged with respect to their response to such stimulation.
  • neurons NA or NB can be selectively stimulated by electrodes 38 and 40 due to the infusion of substances through portions 27-29 of tube 22A.
  • a neuron N1 found in a brain has a cell body CB1 and a nucleus NU1.
  • Neuron N1 can be excited by axon terminals AT1 at synapses SN1-SN2 by an inhibitory neurotransmitter TRB and can be excited by axon terminals AT2 at synapses SN4-SN6 by an excitatory neurotransmitter TRA.
  • Portions 27-29 are used to infuse into the region of neuron N1 one or more of the following agents: an antagonist of transmitter TRB, an agonist of transmitter TRA, an agent to block the reuptake of transmitter TRA, a degradative enzyme for transmitter TRB and potassium.
  • the agents can be infused separately or together in a cocktail.
  • Such infusion leads to partial depolarization of neuron N1 and to a reduced threshold to stimulation by electrodes 38 and 40. That is, after infusion, the amplitude of stimulation required to create action potentials in neuron N1 is reduced compared to the time period before infusion.
  • a neuron N2 found in a brain has a cell body CB2 and a nucleus NU2.
  • Neuron N2 can be inhibited by axon terminals AT3 at synapses SN7-SN8 by an inhibitory neurotransmitter TRB and can be excited by axon terminals AT4 at synapses SN10-SN12 by an excitatory neurotransmitter TRC.
  • a neuron N3 found in a brain has a cell body CB3 and a nucleus NU3.
  • Neuron N3 can be inhibited by axon terminals AT5 at synapses SN14-SN16 by an inhibitory neurotransmitter TRA.
  • Portions 27-29 of tube 22A are used to infuse into the region of neurons N2 and N3 one or more of the following agents: an agonist of transmitter TRA, an agent to block the reuptake of transmitter TRA or an agent to block a degradative enzyme for transmitter TRA.
  • Each of these agents hyperpolarize neuron N3 and increase the potential threshold required to create action potentials in neuron N3. Therefore, neuron N2 can be selectively activated by electrodes 38 and 40 so that an action potential is created in neuron N2 without creating an action potential in neuron N3.
  • Selective activation of neuron N2 also can be achieved by infusing into the region of neurons N2 and N3 one or more of the following agents: an agonist for transmitter TRC, an agent to block the reuptake of transmitter TRC, an agent to block the degrading enzyme for transmitter TRC, an antagonist for transmitter TRB, an agent to enhance the reuptake of transmitter TRB or a degrading enzyme for transmitter TRB.
  • the agents can be infused separately or together in a cocktail.
  • Such infusion leads to partial depolarization of neuron N2 and to a reduced threshold to stimulation by electrodes 38 and 40. That is, after infusion, the amplitude of stimulation required to create action potentials in neuron N2 is reduced compared to the time period before infusion, making it easier to electrically stimulate neuron N2 relative to neuron N3.
  • neurons N4-N6 found in a brain have cells bodies CB4-CB6, respectively, and axons A4-A6, respectively, which are long fibers of passage that typically pass through white tissue in the spinal cord or brain.
  • Cell bodies CB4-CB6 are located at portions of the body somewhat remote from infusion portions 27-29 and electrodes 38 and 40. However, portions of axons A4-A6 pass in the region of infusion portions 27-29 and electrodes 38 and 40.
  • Neurons N7-N9 have cell bodies that are located in the region of infusion portions 27-29 and electrodes 38 and 40.
  • Neuron N7 can be inhibited at axon terminals AT7 by an inhibitory neurotransmitter TRA and excited at axon terminals AT8 by an excitatory neurotransmitter TRB; neuron N9 can be inhibited at axon terminals AT9 by inhibitory neurotransmitter TRA and excited at axon terminals AT10 by excitatory neurotransmitter TRB; and neuron N8 can be inhibited at axon terminals AT11 by inhibitory neurotransmitter TRA and excited at axon terminals AT12 by an excitatory neurotransmitter TRB.
  • FIG. 21 illustrates a modified form of tube 22A in which infusion portion 27 is located more than 0.01 cm from electrodes 38 and 40 and infusion portions 28-29 have been removed.
  • Neuron N10 has a cell body CB10 and an axon A10 that terminates in axon terminals AT14.
  • a neuron N11 can be excited at axon terminals AT14 by an excitatory neurotransmitter TRA.
  • Electrical stimulation of axon A10 causes the release of transmitter TRA at axon terminal AT14.
  • Portion 27 is used to infuse an agent that blocks a degradative enzyme of transmitter TRA or an agent which blocks the reuptake of transmitter TRA.
  • the stimulation of neuron N11 is more potent. That is, more action potentials are generated in neuron N11.
  • FIG. 16A illustrates various times at which infusion and stimulation can be applied by tube 22A.
  • infusion alone can be applied from time T1 to T2
  • infusion and stimulation can be both be applied from time T2 to T3
  • stimulation alone can be applied from time T3 to T4.
  • This regimen might be used in the case when selective activation of one neuronal population is desired.
  • the threshold for electrical activation of one population of neurons can be lowered or raised as needed.
  • a precursor molecule such as L-dopa, is infused to guard against depletion of the transmitter substance dopamine.
  • the infusion of an agent to activate a neuronal population might be alternated with application of electrical stimulation of that same population, as shown in FIG. 16C.
  • the infusion device may be replaced with a static device such as is described in U.S. Pat. No. 4,892,538 which is incorporated by reference.
  • a static device is a device having a semipermeable wall enclosing encapsulated cells capable of secreting the appropriate agent.
  • an implantable device could consist of a polymeric insert with the agent embedded within or on the surface of the polymer in such a way as to be slowly eluted from the polymer over time.
  • Such a device is described in U.S. Pat. No. 4,346,709 "Drug Delivery Devices Comprising Errodable Polymer and Errosion Rate Modifier", Edward Schmitt Inventor, Issued Aug.

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

Techniques using one or more drugs, electrical stimulation or both to treat addictions by means of an implantable signal generator and electrode and an implantable pump and catheter. A catheter is surgically implanted in selected sites in the brain to infuse the drugs, and one or more electrodes are surgically implanted in the brain at selected sites to provide electrical stimulation.

Description

BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to nerve tissue stimulation and infusion techniques, and more particularly relates to such techniques for treating addictions.
2. Description of Related Art
In 1954 Olds and Milner demonstrated the reward circuits of the brain by electrical stimulation of the septal area of the brain ("Positive reinforcement produced by electrical stimulation of septal area and other regions of rat brain.", J Comp Physiol Psychol 47:419-427, 1954) This study marked the beginning of research to understand the nature of addiction.
There are several addicting substances. Addictive substances including opiates, such as heroin, opium and morphine, the sympathomimetics, including cocaine and amphetamines, the sedative-hypnotics including alcohol, benzodiazepines and barbiturates and nicotine which has effects similar to opiods and sympathomimetics. Drug dependence is contrasted with drug abuse by the hallmark symptoms of addiction. Drug addiction is characterized by two features, a craving or compulsion to take the drug and an inability to limit intake of the drug. Additionally, drug dependence is associated with tolerance, which is the loss of effect of the drug with repeated administration and withdrawal, defined as the appearance of physical and behavioral symptoms when the drug is not consumed following chronic use. Sensitization occurs if the repeated administration of a drug leads to an increased response to each dose. Tolerance, sensitization, and withdrawal are phenomena reflecting some sort of plastic change occurring in the central nervous system in response to continued use of a substance. This change is presumably an unstable process that somehow captures the normal mechanisms mediating reinforcement and reward of behavior to motivate the addicted individual to continue consuming the drug in the face of serious social, legal, physical and professional consequences.
Researchers in the field of drug dependence and reward have identified neurological substrates involved in animal motivation and reward and how the neural mechanisms of these substrates are co-opted to result in an addictive state (George F. Koob, "Drugs of abuse: anatomy, pharmacology and function of reward pathways. TiPS--May 1992[Vol. 13]) The mesolimbic dopamine system which innervates the nucleus accumbens has been determined to be the portion of the brain which plays a critical role in mediation of the reinforcing aspects of addiction and the reinforcing aspects of withdrawal.
One theory of how the addictive process occurs is the opponent-process theory. The opponent-process theory describes a process of decreasing positive reward because of increasing tolerance to the consumption of the addicting substance coupled with an increasing negative reinforcement due to withdrawal. The negative reinforcement associated with withdrawal is a motivating factor for continuing consumption of the addicting substance. These processes represent adaptive changes in the nervous system. Memory of the positive reinforcement or "high" coupled with environmental cues which have become conditional positive reinforcers can lead to a relapse of addictive behavior. Researchers have recently recognized certain destructive behaviors such as gambling, shopping, eating and sexual preoccupation collectively referred to as "impulse control" disorders which manifest a common set of symptoms with chemical addictions.
Electrical stimulation of nervous tissue has been used to treat the negative reinforcing symptoms associated with withdrawal from an addictive substance. Transcutaneous nerve stimulation has been proposed as a means of relieving the symptoms of withdrawal form an addictive substance. U.S. Pat. Nos. 3,946,745, 4,841,973, 4,865,048, 5,458,625, and 5,593,432 describe methods and apparatus for stimulating the skin surface e.g. behind the ear to relieve symptoms of addiction. These techniques are described as a more advanced form of acupuncture and are reported to relieve withdrawal symptoms in particular.
Transcranial electrical fields have been applied to the brain (U.S. Pat. No. 4,646,744) to depolarize nerve cells as a means of treating addictions. The effects of transcranial electrical stimulating fields on withdrawal from addictive substances has been enhanced by the coadministration of neuroactive chemical promoter (U.S. Pat. No. 5,084,007).
Certain pharmaceutical agents have been administered to affect the addictive process. Mayer et. al (U.S. Pat. No. 5,556,838) teaches the use of nontoxic NMDA blocking agents coadministered with an addicting substance to prevent the development of tolerance or withdrawal symptoms. The agents are administered acutely through an oral, intravenous, intrathecal, epidural, or intraventricular route. Rose and Levin (U.S. Pat. No. 5,574,052) teaches coadministration of the addictive substance with an antagonist to partially block the pharmacological effects of the substance. The preferred mode of delivery is a transcutaneous patch. Mendelson and Mello propose use of a mixed opiate agonist/antagonist to treat cocaine and opiate addiction. Downs (U.S. Pat. No. 5,232,934) teaches administration of 3-phenoxypyridine to treat addiction. Imperato and Romer (U.S. Pat. Nos. 5,039,680 and 5,198,459) teach the use of a serotonin antagonist as a treatment for chemical addiction. Nestler et. al. teach the infusion of the growth factors BDNF or NT-4 to inhibit or reverse the neurological adaptive changes that correlate with the behavioral changes of an addictive disorder.
Inotophoretic delivery through the skin of agents to treat addiction is described in U.S. Pat. Nos. 5,415,629 and 5,538,503. Alternatively, Yolles teaches delivery of drugs to treat addictions by eluting them from a polymeric material preferably implanted under the skin. (Curt he does describe lining a catheter or injecting into blood stream--can I focus on the subcutaneous application???)
Alternatively, Sagen (U.S. Pat. No. 5,762,925) teaches implantation of encapsulated adrenal medullary cells into the central nervous system so that they might release substances that inhibit the development of opiod intolerance.
SUMMARY OF THE INVENTION
A preferred form of the invention uses one or more drugs and/or electrical stimulation to treat addictions. In one embodiment, the treatment is carried out by an implantable pump and a catheter having a proximal end coupled to the pump and having a discharge portion for infusing therapeutic dosages of the one or more drugs into a predetermined infusion site in brain tissue. In another embodiment, the treatment may be carried out by an implantable signal generator and an implantable electrode having a proximal end coupled to the signal generator and having a stimulation portion for electrically stimulating a predetermined stimulation site in the brain tissue. In a further embodiment, treatment is carried out by a combined infusion of therapeutic dosages of the one or more drugs and electrical stimulation of a predetermined stimulation sited in the brain tissue.
According to one embodiment of the invention, the electrical stimulation, drug infusion or both can block excitation of neural activity in the Locus coeruleus, thereby treating the cravings associated with addiction.
According to a second embodiment of the invention, the electrical stimulation, drub infusion or both can block the increased activity of dopaminergic neurons in the Nucleus Accumbens, thereby limiting the positive reinforcing effects associated with addiction.
By using the foregoing techniques, addiction and impulse control disorders can be controlled to a degree unattainable by prior art methods or apparatus.
BRIEF DESCRIPTION OF THE DRAWINGS
These and other advantages and features of the invention will become apparent upon reading the following detailed description and referring to the accompanying drawings in which like numbers refer to like parts throughout and in which:
FIG. 1 is a diagrammatic illustration of a combined catheter and electrode implanted in a brain according to a preferred embodiment of the present invention, and a signal generator and pump coupled to the combined catheter and electrode;
FIG. 2 is a cross-sectional view of the catheter-electrode of FIG. 1 taken along line 2--2 of FIG. 3;
FIG. 3 is a diagrammatic view of the catheter-electrode shown in FIG. 1;
FIG. 4 is a diagrammatic illustration of a catheter and a sensor implanted in a brain and a pump coupled to the catheter and sensor;
FIG. 5 is a diagrammatic illustration of a lead and a sensor implanted in a brain and a signal generator coupled to the lead and sensor;
FIG. 6 is a diagrammatic illustration of a combined lead and catheter and a sensor implanted in a brain and a signal generator and pump coupled to the combined catheter and electrode and sensor;
FIG. 7 is a diagrammatic illustration of a separate lead and catheter and a sensor implanted in a brain and a signal generator and pump coupled to the lead, catheter and sensor;
FIG. 8 is a schematic block diagram of a sensor and analog to digital converter circuit used in the preferred embodiment of the invention;
FIG. 9 is a flow chart illustrating a preferred form of a microprocessor program for utilizing the sensor to control drug dosage administered to the brain;
FIG. 10 is a schematic block diagram of a microprocessor and related circuitry for utilizing the sensor to control stimulation administered to the brain;
FIGS. 11-15 are flow charts illustrating a preferred form of microprocessor program for generating stimulation pulses to be administered to the brain;
FIGS. 16A-16C are timing diagrams showing the relationship between the administration of drugs and electrical stimulation to nerve tissue; and
FIGS. 17-21 are diagrammatical views of the catheter-electrode shown in FIG. 1 arranged adjacent various types of neural tissue.
DESCRIPTION OF THE PREFERRED EMBODIMENTS
Referring to FIG. 1, a pump or device 10 made in accordance with the preferred embodiment may be implanted below the skin of a patient. The device has a port 14 into which a hypodermic needle can be inserted through the skin to inject a quantity of a liquid agent, such as a medication or drug. The liquid agent is delivered from device 10 through a catheter port 20 into a catheter 22. Catheter 22 is positioned to deliver the agent to specific infusion sites in a brain (B). Device 10 may take the form of the like-numbered device shown in U.S. Pat. No. 4,692,147 (Duggan) ("the '147 Patent"), assigned to Medtronic, Inc., Minneapolis, Minn., which is incorporated by reference. An embodiment of pump 10 may be found in the Synchromedâ„¢ Infusion System manufactured by Medtronic, Inc. of Minneapolis, Minn. However, pump 10 may take the form of any device used for moving fluid from a reservoir.
The distal end of catheter 22 terminates in a cylindrical hollow tube 22A having a distal end 25 implanted into a portion of the brain by conventional stereotactic surgical techniques. A semispherical portion 23 (FIG. 3) at the distal end 25 of tube 22A provides a rounded profile for minimizing tissue disruption during insertion. End 25 is provided with microporous portions 27-29 (FIG. 3) to allow infusion and filtering of a liquid agent. Microporous portions 27-29 are preferably composed of a porous material such as polysulfone hollow fiber, manufactured by Amicon, although polyethylene, polyamides, polypropylene and expanded polytetrafluorethylene (ePTFE) are also suitable.
In a preferred embodiment, the preferred pore size is approximately less than or equal to 0.22 microns. It is preferred that the maximum pore size be less than or equal to approximately 0.22 microns to prevent any derelict bacterial agents that may be present inside the catheter 22A from entering into the brain B. Furthermore, at larger pore sizes, there is the potential for tissue in-growth that may restrict the flow of agents out of the microporous portions 27-29. Alternatively, end 25 may be provided with multiple holes or slits in which case filtering of the liquid agent may occur within pump 10.
Catheter 22 could take the form of a lead catheter combination developed for use outside of the dural covering of the spinal cord to treat pain which is shown in FIG. 1 in U.S. Pat. No. 5,423,877 (Mackey) which is incorporated by reference. Alternatively, catheter 22 could take the form depicted in FIGS. 1-4 in U.S. Pat. Nos. 5,119,832 and 5,458,631 (Xavier) which is incorporated by reference also developed for use outside of the dura to treat pain in which the center lumen 34 terminates in a single opening at the distal end 25 of catheter 22A.
Referring to FIG. 2, tube 22A includes an outer cylindrical insulating jacket 30 and an inner cylindrical insulating jacket 32 that defines a cylindrical catheter lumen 34. A multifilar coil of wire 36 is embedded in tube 22A as shown. Alternatively, wire 36 could consist of multifilar stranded wire.
When selecting the tube 22A used with a particular drug or agent, care should be taken to ensure that the particular agent will be compatible with the material from which the inner cylindrical insulating jacket 32 is composed. The inner cylindrical insulating jacket 32 and outer cylindrical insulating jacket 30 should be sufficiently flexible to facilitate insertion. The outer cylindrical insulating jacket 30 should be biocompatible. While it is desirable to have the inner insulating jacket 32 be biocompatible it may not be absolutely necessary provided the inner insulating layer can be kept from contacting the biological tissue. An enhanced tear resistant silicone elastomer or polyurethane are examples of materials that could be used. A durometer shore value of 80 is preferred.
Tube 22A is surgically implanted through a hole in the skull 123 and catheter 22 is implanted between the skull and the scalp 125 as shown in FIG. 1. A stylet may be placed into the center of tube 22A to give it stiffness when introducing the tube into the brain. After the stylet is removed, center lumen 34 constitutes a catheter which can be used to infuse an agent, including a drug. Catheter 22 is joined to implanted device 10 in the manner shown. Tube 22A may be continuous with tube 22 or there may be an interveining connection most likely at the burr hole or located somewhere along the subcutaneous path.
Catheter 22 may be divided into twin tubes, tube 22A and a second tube (not shown), that are implanted into the brain bilaterally. Alternatively, the second tube may be supplied with drugs from a separate catheter and pump and with electrodes from a separate signal generator.
Referring again to FIG. 1, a system or device 16 made in accordance with the preferred embodiment also may be implanted below the skin of a patient. Device 16 may take the form of a signal generator Model 7424 manufactured by Medtronic, Inc. of Minneapolis, Minn. under the trademark Itrel II.
The distal end of tube 22A terminates in stimulation electrodes 38 and 40 (FIG. 3). Each of electrodes 38 and 40 is individually connected to device 16 through a conductor in wire bundle 36 (FIG. 2). The wires exit catheter 22 to form a cable 42 which is joined to implanted signal generator 16 in the manner shown in FIG. 1. While the preferred embodiment shows two electrodes on tube 22A (FIG. 3), some brain locations may require a greater number. In addition, tube 22A may have only one electrode using a portion of the case of the signal generator 16 (FIG. 1) as the reference electrode. Furthermore, in some instances infusion conduit 34 (FIG. 2) and conductor conduit 36 may not be concentric tubes but rather separate conduits located beside each other in a common tube as is embodied in FIG. 6 of U.S. Pat. No. 5,458,629 (Baudino et.al.), incorporated by reference.
Signal generator 16 is implanted in a human body, preferably in a subcutaneous pocket located over the chest cavity or the abdomen. While showed as separate devices in FIG. 1, devices 10 and 16 could be incorporated into a common device.
The present invention may preferably be implemented by providing seven different drug dosages from 0 dosage to a 1.0 ml dosage with 0.1 ml increments between choices. The time interval between dosages can preferably be selected between one and twelve hours in seven choices. This is the same type of dosage and interval described in connection with device 10 shown in the '147 Patent (column 5, beginning at line 63). The seven drug dosages and corresponding time increments may be loaded into RAM 102a (FIG. 11B of the '147 Patent). The selected dosage and interval of a drug is then delivered, as described in the '147 Patent, through catheter 22 and tube 22A to a selected location in the brain appropriate for the treatment of anxiety disorders.
The type of drugs administered by device 10 into the brain depend on the specific location at which distal end 25 of tube 22A is surgically implanted. The appropriate brain location to surgically implant distal end 25, whether the action is intended to block the positive or negative reinforcing effects, the desired action of the agent on the neurons at that location and the types of drug agents useful at that location are provided in the following Table I:
                                  TABLE I                                 
__________________________________________________________________________
EFFECT ON NEURONS                                                         
             PORTION OF BRAIN                                             
                         DRUG                                             
__________________________________________________________________________
ACTIONS AFFECTING POSITIVE REINFORCEMENT OF ADDICTION                     
DECREASE EXCITATION                                                       
             DORSAL MEDIAL                                                
                         GLUTAMATE or                                     
             THALAMUS    ASPARTATE ANTAGONIST/                            
                         DEGRADING ENZYME/                                
                         Anesthetic                                       
INCREASE INHIBITION                                                       
             DORSAL MEDIAL                                                
                         GABA AGONIST/                                    
             THALAMUS    REUPTAKE BLOCKER/                                
                         DEGRADING ENZYME                                 
                         BLOCKER                                          
INCREASE EXCITATION                                                       
             INTERNAL GLOBUS                                              
                         GLUTAMATE or                                     
             PALLIDUS (Gpi)/                                              
                         ASPARTATE AGONIST/                               
             SUBSTANTIA NIGRA                                             
                         REUPTAKE BLOCKER                                 
             RETICULATA (SNr)                                             
DECREASE INHIBITION                                                       
             GPi/SNr     GABA ANTAGONIST/                                 
                         DEGRADING ENZYME                                 
INCREASE EXCITATION                                                       
             STN         GLUTAMATE or                                     
                         ASPARTATE AGONIST/                               
                         REUPTAKE BLOCKER                                 
DECREASE INHIBITION                                                       
             STN         GABA ANTAGONIST/                                 
                         DEGRADING ENZYME                                 
DECREASE EXCITATION                                                       
             EXTERNAL GLOBUS                                              
                         GLUTAMATE or                                     
             PALLIDUS (GPe)                                               
                         ASPARTATE ANTAGONIST/                            
                         DEGRADING ENZYME/                                
                         Anesthetic                                       
INCREASE INHIBITION                                                       
             GPe         GABA AGONIST/                                    
                         REUPTAKE BLOCKER/                                
                         DEGRADING ENZYME                                 
                         BLOCKER                                          
DECREASE EXCITATION                                                       
             NUCLEUS ACCUMBENS                                            
                         DOPAMINE ANTAGONIST/                             
                         GLUTAMATE or                                     
                         ASPARTATE ANTAGONIST/                            
                         Anesthetic                                       
INCREASE INHIBITION                                                       
             NUCLEUS ACCUMBENS                                            
                         GABA AGONIST/                                    
                         REUPTAKE BLOCKER/                                
                         DEGRADING ENZYME                                 
                         BLOCKER                                          
DECREASE EXCITATION                                                       
             CENTRAL NUCLEUS OF                                           
                         DOPAMINE ANTAGONIST/                             
             THE AMYGDALA                                                 
                         Anesthetic                                       
INCREASE INHIBITION                                                       
             CENTRAL NUCLEUS OF                                           
                         GABA AGONIST/                                    
             THE AMYGDALA                                                 
                         REUPTAKE BLOCKER/                                
                         DEGRADING ENZYME                                 
                         BLOCKER                                          
ACTIONS AFFECTING NEGATIVE REINFORCEMENT OF ADDICTION                     
INCREASE INHIBITION                                                       
             LOCUS COERULEUS                                              
                         GABA AGONIST/                                    
                         REUPTAKE BLOCKER                                 
__________________________________________________________________________
Coordinates for the portions of the brain described in Table I are as follows:
              TABLE II                                                    
______________________________________                                    
            MEDIAL-    DORSAL-    ANTERIOR-                               
            LATERAL    VENTRAL    POSTERIOR                               
BRAIN REGION                                                              
            DIMENSION  DIMENSION  DIMENSION                               
______________________________________                                    
Dorsal Medial                                                             
            0.0 to 1.0 0.2 to 1.7 0.1 to -1.1                             
Nucleus,                                                                  
Medial Nucleus of                                                         
Thalamus                                                                  
Gpi         0.5 to 2.0   0.5 to -0.7                                      
                                  0.7 to 2.0                              
SNr         0.5 to 1.5 -0.6 to -1.5                                       
                                  0.7 to -0.7                             
STN         0.5 to 2.0   0.0 to -1.0                                      
                                  0.6 to -1.0                             
GPe         1.6 to 2.7   1.0 to -1.0                                      
                                  2.0 to -1.0                             
Nucleus Accumbens                                                         
            0.5 to 3.0 -1.0 to 2.0                                        
                                  1.0 to 3.0                              
Amygdala    1.0 to 3.0 -1.2 to -2.5                                       
                                  0.5 to 1.7                              
Locus Coeruleus                                                           
            0.3 to 1.0 -1.8 to -3.0                                       
                                  -1.2 to -2.5                            
______________________________________
In the foregoing table: the medial-lateral dimensions are relative to midline of the brain; the anterior-posterior dimensions are relative to the midpoint between the anterior commissure and posterior commissure with negative indicating the posterior direction; the dorsal-ventral dimensions are relative to a line connecting the midpoints of the anterior and posterior commissures with negative being ventral to; all dimensions are in centimeters.
Alternatively, these agents might be infused into the lateral ventricle or third ventricle of the brain or just beneath the dura above the cortex or in the intrathecal space. In this instance the drug would diffuse to the appropriate site of action.
Exemplary liquid agents which provide the desired actions identified in Table I, ranges of dosages and concentrations for the liquid agents are provided in the following Table III:
              TABLE III                                                   
______________________________________                                    
                             DOSING                                       
DRUG CLASS SPECIFIC DRUG     RANGE                                        
______________________________________                                    
Glutamate Agonist                                                         
           D-Cycloserine     1-10     muM                                 
           L-AP4             1-10     muM                                 
           Carboxyphenylglycine                                           
                             10-500   muM                                 
           L-glutamic acid   1-100    muM                                 
           cis-Piperidine-2,3-dicarboxylic                                
                             1-10     muM                                 
           acid                                                           
           (+/-)-trans-ACPD  1-10     muM                                 
           L-AP4             1-10     muM                                 
Glutamate  MK801(dizocilpine)                                             
                             1-20     muM                                 
Antagonists                                                               
           ketamine Hcl      5-50     muM                                 
           AP-3              1-10     muM                                 
           Dextromethorphan  1-100    muM                                 
           MCPD              0.02-10  muM                                 
           dextrorphan tartrate                                           
                             1-100    muM                                 
           CNQX              1-100    muM                                 
GABA Agonists                                                             
           baclofen          0.1-10   muM                                 
           muscimol HBr      100-500  muM                                 
GABA Antagonists                                                          
           Gabazine          1-50     muM                                 
           Saclofen          0.5-25   muM                                 
           Bicuulline        1-100    muM                                 
           picrotoxin        10-100   muM                                 
Dopamine   (+) apomorphine Hcl                                            
                             5-20     muM                                 
Antagonist spiperone Hcl     0.1-10   muM                                 
           haloperidol       10-100   muM                                 
           (-) Sulpiride     0.05-1   muM                                 
Dopamine Agonist                                                          
           methanesulfonate  1-10     muM                                 
           (-) apomorphine   10-30    muM                                 
           pergolide                                                      
GABA Re-uptake                                                            
           Tiagabine         0.001-10 muM                                 
blocker                                                                   
GABA degrading                                                            
           Vigabatrin        0.005-10 muM                                 
enzyme blocker                                                            
Anesthetic Lidocaine hydrochloride                                        
                             5-20     muM                                 
______________________________________
In Table II, muM means millimicromolar.
Microprocessor 100 within device 10 can be programmed so that a controlled amount of drug described in Table III can be delivered to the specific brain sites described in Table I.
The applicant has discovered that both the positive and negative reinforcement of addictive activity can be treated by electrically stimulating brain tissue either alone or while drugs are being administered as described above. The stimulation can be achieved by an ITREL II signal generator implemented as signal generator 16 (FIG. 1).
Electrical stimulation of neural tissue may be implemented by providing pulses to electrodes 38 and 40 (FIG. 3) preferably having amplitudes of 0.1 to 20 volts, pulse widths varying from 0.02 to 1.5 milliseconds, and repetition rates preferably varying from 2 to 2500 Hz. Pulses with the selected characteristics are then delivered from signal generator 16 through cable 42, catheter 22, tube 22A and electrodes 38 and 40 to the targeted tissue within brain B. The appropriate stimulation pulses are generated by signal generator 16 based on the programmed values established by the clinician. The type of stimulation administered by signal generator 16 to the brain depends on the specific location at which the electrodes 38 and 40 of tube 22A are surgically implanted and the desired action on the neurons at that location. If the neuronal activity is to be blocked, signal generator 16 will be programmed with a frequency preferably in the range 50 to 2500 HZ. If the neuronal activity is to be facilitated, the stimulus frequency is chosen preferably in the range of 2 to 100 Hz.
The appropriate stimulation for use in connection with the specific locations of the brain in which tube 22A terminates, together with the effect of the stimulation on that portion of the brain for an addictive disorder is provided in the following Table IV:
                                  TABLE IV                                
__________________________________________________________________________
EFFECT        STIMULUS TYPE LOCATION                                      
__________________________________________________________________________
DECREASE EXCITATION OF                                                    
              HIGH FREQ. BLOCKING                                         
                            DORSAL MEDIAL                                 
DORSAL MEDIAL STIMULATION   THALAMUS                                      
THALAMUS                                                                  
INCREASE INHIBITION                                                       
              LOW FREQ. ACTIVATING                                        
                            Pallido-thalamic axons (AL and                
OF DORSAL MEDIAL                                                          
              STIMULATION   LT)                                           
THALAMUS                                                                  
INCREASE EXCITATION OF                                                    
              LOW FREQ. ACTIVATING                                        
                            GPi/SNr                                       
GPi/SNr       STIMULATION                                                 
INCREASE EXCITATION OF                                                    
              LOW FREQ. ACTIVATING                                        
                            Subthalamic to pallidal fiber                 
GPi/SNr       STIMULATION   tracts                                        
INCREASE EXCITATION OF                                                    
              LOW FREQ. STIMULATION                                       
                            STN Nucleus                                   
STN                                                                       
DECREASE INHIBITION OF                                                    
              HIGH FREQ. BLOCKING                                         
                            GPe                                           
STN           STIMULATION                                                 
DECREASE EXCITATION OF                                                    
              HIGH FREQ. BLOCKING                                         
                            GPe                                           
GPe           STIMULATION                                                 
INCREASE INHIBITION                                                       
              LOW FREQ. SIMULATION                                        
                            Neostriatum to Gpe fibers (i.e.,              
OF GPe                      border of nucleus)                            
DECREASE EXCITATION OF                                                    
              HIGH FREQ. BLOCKING                                         
                            NUCLEUS ACCUMBENS                             
NUCLEUS ACCUMBENS                                                         
              STIMULATION                                                 
DECREASE EXCITATION                                                       
              HIGH FREQ. BLOCKING                                         
                            AMYGDALA                                      
OF CENTRAL NUCLEUS OF                                                     
              STIMULATION                                                 
AMYGDALA                                                                  
ACTIONS AFFECTING NEGATIVE REINFORCEMENT OF ADDICTION                     
BLOCK ACTIVITY IN                                                         
              HIGH FREQUENCY                                              
                            LOCUS COERULEUS                               
LOCUS COERULEUS                                                           
              BLOCKING STIMULATION                                        
__________________________________________________________________________
Coordinates for the portions of the brain described in Table IV are found in Table II.
A microprocessor within signal generator 16 can be programmed so that the desired stimulation can be delivered to the specific brain sites described in Table II.
The system shown in FIG. 1 is an open-loop system. The microcomputer algorithm programmed by the clinician sets the stimulation parameters of signal generator 16 and/or infusion rates of infusion pump 10. This algorithm may change the parameter values over time but does so independent of any changes in symptoms the patient may be experiencing. Alternatively, the closed-loop systems show in FIGS. 4-7 which incorporate sensor 130 to provide feedback could be used to provide enhanced results.
FIG. 4 depicts an infusion pump 10 connected through tube 22 to a distal portion 22A and a separate sensor portion 130. FIG. 5 depicts a signal generator 16 connected through cable 42' which has a distal cable 42'A with electrodes 38 and 40 located at the distal end and a sensor portion 130. The devices in FIGS. 4 and 5 provide "closed-loop" infusion of medication and "closed-loop" stimulation respectively.
Alternatively, the device in FIG. 6 allows for the combination of infusion and stimulation both therapies being controlled by a feed back sensor 130. In FIG. 6, the stimulation electrodes 38 and 40 are made a part of tube 22A as depicted in FIG. 3.
Alternatively, referring to FIG. 7 the stimulation electrodes 38 and 40 could be located on a separate tube 22B away from the microporous regions 27-29 located on tube 22A. This would allow delivery of stimulation to a different site in brain B than the site where medication is delivered. The sensor 130 is located at still a different site in brain B. Under certain circumstances it may be desirable to have sensor 130 physically located on either tube 22A or tube 22B.
A sensor 130 is implanted into a portion of a patient's body suitable for detecting symptoms of the disorder being treated. Sensor 130 is adapted to sense an attribute of the symptom to be controlled or an important related symptom. The positive reinforcing actions of reward are manifest by an increased level of neuronal activity in the Nucleus Accumbens. A preferred embodiment of sensor 130 would sense the increased neuronal activity of the Nucleus Accumbens.
Brain EEG (e.g., cortical potentials recorded above the neurons controlling specific aspects of behavior associated with the neurological disorder) also may be detected by sensor 130. In this case, sensor 130 would take the form of an electrode with impedence values preferably chosen to optimize recording of electrical signals.
Yet another form of sensor 130 would include a device capable of detecting nerve compound action potentials (e.g., neuronal information in pathways of the brain concerned with the neuronal disorder.
Sensor 130 also may take the form of a device capable of detecting single nerve cell or axon activity that is related to the pathways at the cause of the symptom, or that reflects sensations which are elicited by the symptom. Such a sensor may be located deep in the brain. For such detecting, sensor 130 may take the form of an electrode inserted into the internal capsule, cortex or basal ganglia of the brain. Signals of any kind that are received by the sensor may by amplified before transmission to circuitry contained within device 10 or device 16.
Sensor 130 may take the form of a transducer consisting of an electrode with an ion selective coating applied which is capable of directly transducing the amount of a particular transmitter substance or its breakdown by-products found in the interstitial space of a region of the brain such as the ventral lateral thalamus. The level of the interstitial transmitter substance is an indicator of the relative activity of the brain region. An example of this type of transducer is described in the paper "Multichannel semiconductor-based electrodes for in vivo electrochemical and electrophysiological studies in rat CNS" by Craig G. van Horne, Spencer Bement, Barry J. Hoffer, and Greg A. Gerhardt, published in Neuroscience Letters, 120 (1990) 249-252.
Sensor 130 may be external to the body communicating with the implanted portions through telemetry.
Other sensors such as carbon dioxide gas sensors or other sensors that can detect the physiological parameters reflecting the state of the neurological disorder will be clear to those skilled in the art. Referring to FIG. 8, the output of sensor 130 is coupled by a cable 132 comprising conductors 134 and 135 to the input of analog to digital converter 140. Alternatively, the output of an external feedback sensor would communicate with the implanted pulse generator or pump through a telemetry downlink. The output of the analog to digital converter is connected to terminals EF2 BAR and EF3 BAR shown in FIG. 11A of U.S. Pat. No. 4,692,147 ("'147 Patent"). Before converter 140 is connected to the terminals, the demodulator 101 currently shown in FIG. 11A would be disconnected. A drug can be delivered essentially continuously (within the constraints of the particular delivery device being used) or it may be delivered during intermittent intervals coordinated to reflect the half-life of the particular agent being infused or with circadian rhythms. As an example, the cravings or negative reinforcments may normally subside at night when the person is sleeping so the drug delivery rates might be reduced to coincide with the hours between 10 p.m. and 7 a.m.
Microprocessor 100 within device 10 can be programmed so that a controlled amount of drug can be delivered to the specific brain sites described in Table I. Alternatively, sensor 130 can be used with a closed loop feedback system in order to automatically determine the level of drug delivery necessary to alleviate the symptoms of the neurological disorder.
The applicants have discovered that the efficacy of treatment may be enhanced if the neural tissue is stimulated while drugs are being administered as described above. The stimulation can be achieved by a modified form of the ITREL II signal generator implemented as signal generator 16 (FIG. 1) which is described in FIG. 10. The output of sensor 130 is coupled by cable 132, comprising conductors 134 and 135, to the input of an analog to digital converter 206. Alternatively, the output of an external sensor would communicate with the implanted pulse generator through a telemetry downlink.
For some types of sensors, a microprocessor and analog to digital converter will not be necessary. The output from sensor 130 can be filtered by an appropriate electronic filter in order to provide a control signal for signal generator 16. An example of such a filter is found in U.S. Pat. No. 5,259,387 "Muscle Artifact Filter, Issued to Victor de Pinto on Nov. 9, 1993.
The output of the analog to digital converter 206 is connected to a microprocessor 200 through a peripheral bus 202 including address, data and control lines. Microprocessor 200 processes the sensor data in different ways depending on the type of transducer in use. When the signal on sensor 130 exceeds a level programmed by the clinician and stored in a memory 204, increasing amounts of stimulation will be applied through an output driver 224.
The stimulus pulse frequency is controlled by programming a value to a programmable frequency generator 208 using bus 202. The programmable frequency generator provides an interrupt signal to microprocessor 200 through an interrupt line 210 when each stimulus pulse is to be generated. The frequency generator may be implemented by model CDP1878 sold by Harris Corporation.
The amplitude for each stimulus pulse is programmed to a digital to analog converter 218 using bus 202. The analog output is conveyed through a conductor 220 to an output driver circuit 224 to control stimulus amplitude.
Microprocessor 200 also programs a pulse width control module 214 using bus 202. The pulse width control provides an enabling pulse of duration equal to the pulse width via a conductor. Pulses with the selected characteristics are then delivered from signal generator 16 through cable 22 and lead 22A or 22B to the target locations of a brain B.
Microprocessor 200 executes an algorithm shown in FIGS. 11-15 in order to provide stimulation with closed loop feedback control. At the time the stimulation signal generator 16 or alternative device in which the stimulation and infusion functions are combined is implanted, the clinician programs certain key parameters into the memory of the implanted device via telemetry. These parameters may be updated subsequently as needed. Step 400 in FIG. 11 indicates the process of first choosing whether the neural activity at the stimulation site is to be blocked or facilitated (step 400(1)) and whether the sensor location is one for which an increase in the neural activity at that location is equivalent to an increase in neural activity at the stimulation target or vice versa (step 400(2)). Next the clinician must program the range of values for pulse width (step 400(3)), amplitude (step 400(4)) and frequency (step 400(5)) which signal generator 16 may use to optimize the therapy. The clinician may also choose the order in which the parameter changes are made (step 400(6)). Alternatively, the clinician may elect to use default values.
The algorithm for selecting parameters is different depending on whether the clinician has chosen to block the neural activity at the stimulation target or facilitate the neural activity. FIG. 11 details steps of the algorithm to make parameter changes.
The algorithm uses the clinician programmed indication of whether the neurons at the particular location of the stimulating electrode are to be facilitated or blocked in order to decide which path of the parameter selection algorithm to follow (step 420, FIG. 12). If the neuronal activity is to be blocked, signal generator 16 first reads the feedback sensor 130 in step 421. If the sensor values indicate the activity in the neurons is too high (step 422), the algorithm in this embodiment first increases the frequency of stimulation in step 424 provided this increase does not exceed the preset maximum value set by the physician. Step 423 checks for this condition. If the frequency parameter is not at the maximum, the algorithm returns to step 421 through path 421A to monitor the feed back signal from sensor 130.
If the frequency parameter is at the maximum, the algorithm next increases the pulse width in step 426 (FIG. 13), again with the restriction that this parameter has not exceeded the maximum value as checked for in step 425 through path 423A. Not having reached maximum pulse width, the algorithm returns to step 421 to monitor the feedback signal from sensor 130. Should the maximum pulse width have been reached, the algorithm next increases amplitude in a like manner as shown in steps 427 and 428. In the event that all parameters reach the maximum, a notification message is set in step 429 to be sent by telemetry to the clinician indicating that device 16 is unable to reduce neural activity to the desired level.
If, on the other hand, the stimulation electrode is placed in a location which the clinician would like to activate in order to alter the symptoms of the neurological disorder, the algorithm would follow a different sequence of events. In the preferred embodiment, the frequency parameter would be fixed at a value chosen by the clinician to facilitate neuronal activity in step 430 (FIG. 14) through path 420A. In steps 431 and 432 the algorithm uses the values of the feedback sensor to determine if neuronal activity is being adequately controlled. In this case, inadequate control indicates that the neuronal activity of the stimulation target is too low. Neuronal activity is increased by first increasing stimulation amplitude (step 434) provided it doesn't exceed the programmed maximum value checked for in step 433. When maximum amplitude is reached, the algorithm increases pulse width to its maximum value in steps 435 and 436 (FIG. 15). A lack of adequate alteration of the symptoms of the neurological disorder, even though maximum parameters are used, is indicated to the clinician in step 437. After steps 434, 436 and 437, the algorithm returns to step 431 through path 431A, and the feedback sensor again is read.
It is desirable to reduce parameter values to the minimum level needed to establish the appropriate level of neuronal activity in, for example, the target brain nucleus. Superimposed on the algorithm just described is an additional algorithm to readjust all the parameter levels downward as far as possible. In FIG. 11, steps 410 through 415 constitute the method to do this. When parameters are changed, a timer is reset in step 415. If there is no need to change any stimulus parameters before the timer has counted out, then it may be possible due to changes in neuronal activity to reduce the parameter values and still maintain appropriate levels of neuronal activity in the target neurons. At the end of the programmed time interval, signal generator 16 tries reducing a parameter in step 413 to determine if control is maintained. If it is, the various parameter values will be ratcheted down until such time as the sensor values again indicate a need to increase them. While the algorithms in FIGS. 11-15 follow the order of parameter selection indicated, other sequences may be programmed by the clinician.
The foregoing techniques for simultaneous drug infusion and electrical stimulation can be applied to neural tissue in general, and are not limited to the previously described locations in the brain. FIG. 17 describes one such application in which type A neurons, such as NA, are located in the same region as type B neurons, such as NB which can typically be found in a brain. By infusing various agents through portions 27-29, neurons NA can be inhibited or excited with respect to their response to electrical stimulation provided by electrodes 38 and 40, while neurons NB remain unchanged with respect to their response to such stimulation. Thus, neurons NA or NB can be selectively stimulated by electrodes 38 and 40 due to the infusion of substances through portions 27-29 of tube 22A.
Referring to FIG. 18, a neuron N1 found in a brain has a cell body CB1 and a nucleus NU1. Neuron N1 can be excited by axon terminals AT1 at synapses SN1-SN2 by an inhibitory neurotransmitter TRB and can be excited by axon terminals AT2 at synapses SN4-SN6 by an excitatory neurotransmitter TRA. Portions 27-29 are used to infuse into the region of neuron N1 one or more of the following agents: an antagonist of transmitter TRB, an agonist of transmitter TRA, an agent to block the reuptake of transmitter TRA, a degradative enzyme for transmitter TRB and potassium. The agents can be infused separately or together in a cocktail. Such infusion leads to partial depolarization of neuron N1 and to a reduced threshold to stimulation by electrodes 38 and 40. That is, after infusion, the amplitude of stimulation required to create action potentials in neuron N1 is reduced compared to the time period before infusion.
Referring to FIG. 19, a neuron N2 found in a brain has a cell body CB2 and a nucleus NU2. Neuron N2 can be inhibited by axon terminals AT3 at synapses SN7-SN8 by an inhibitory neurotransmitter TRB and can be excited by axon terminals AT4 at synapses SN10-SN12 by an excitatory neurotransmitter TRC.
A neuron N3 found in a brain has a cell body CB3 and a nucleus NU3. Neuron N3 can be inhibited by axon terminals AT5 at synapses SN14-SN16 by an inhibitory neurotransmitter TRA. Portions 27-29 of tube 22A are used to infuse into the region of neurons N2 and N3 one or more of the following agents: an agonist of transmitter TRA, an agent to block the reuptake of transmitter TRA or an agent to block a degradative enzyme for transmitter TRA. Each of these agents hyperpolarize neuron N3 and increase the potential threshold required to create action potentials in neuron N3. Therefore, neuron N2 can be selectively activated by electrodes 38 and 40 so that an action potential is created in neuron N2 without creating an action potential in neuron N3.
Selective activation of neuron N2 also can be achieved by infusing into the region of neurons N2 and N3 one or more of the following agents: an agonist for transmitter TRC, an agent to block the reuptake of transmitter TRC, an agent to block the degrading enzyme for transmitter TRC, an antagonist for transmitter TRB, an agent to enhance the reuptake of transmitter TRB or a degrading enzyme for transmitter TRB. The agents can be infused separately or together in a cocktail. Such infusion leads to partial depolarization of neuron N2 and to a reduced threshold to stimulation by electrodes 38 and 40. That is, after infusion, the amplitude of stimulation required to create action potentials in neuron N2 is reduced compared to the time period before infusion, making it easier to electrically stimulate neuron N2 relative to neuron N3.
Referring to FIG. 20, neurons N4-N6 found in a brain have cells bodies CB4-CB6, respectively, and axons A4-A6, respectively, which are long fibers of passage that typically pass through white tissue in the spinal cord or brain. Cell bodies CB4-CB6 are located at portions of the body somewhat remote from infusion portions 27-29 and electrodes 38 and 40. However, portions of axons A4-A6 pass in the region of infusion portions 27-29 and electrodes 38 and 40. Neurons N7-N9 have cell bodies that are located in the region of infusion portions 27-29 and electrodes 38 and 40. Neuron N7 can be inhibited at axon terminals AT7 by an inhibitory neurotransmitter TRA and excited at axon terminals AT8 by an excitatory neurotransmitter TRB; neuron N9 can be inhibited at axon terminals AT9 by inhibitory neurotransmitter TRA and excited at axon terminals AT10 by excitatory neurotransmitter TRB; and neuron N8 can be inhibited at axon terminals AT11 by inhibitory neurotransmitter TRA and excited at axon terminals AT12 by an excitatory neurotransmitter TRB. Portions 27-29 are used to infuse an agonist of transmitter TRA, a reuptake blocker to transmitter TRA, a degrading enzyme blocker to transmitter TRA or an antagonist or degrading enzyme to transmitter TRB to raise the stimulation threshold of neurons N7-N9. Neurons N4-N6 are not affected by the infusion and can be selectively activated by stimulation supplied by electrodes 38 and 40.
FIG. 21 illustrates a modified form of tube 22A in which infusion portion 27 is located more than 0.01 cm from electrodes 38 and 40 and infusion portions 28-29 have been removed. Neuron N10 has a cell body CB10 and an axon A10 that terminates in axon terminals AT14. A neuron N11 can be excited at axon terminals AT14 by an excitatory neurotransmitter TRA. Electrical stimulation of axon A10 causes the release of transmitter TRA at axon terminal AT14. Portion 27 is used to infuse an agent that blocks a degradative enzyme of transmitter TRA or an agent which blocks the reuptake of transmitter TRA. For each pulse administered by electrodes 38 and 40, the stimulation of neuron N11 is more potent. That is, more action potentials are generated in neuron N11.
FIG. 16A illustrates various times at which infusion and stimulation can be applied by tube 22A. For example, infusion alone can be applied from time T1 to T2, infusion and stimulation can be both be applied from time T2 to T3, and stimulation alone can be applied from time T3 to T4. This regimen might be used in the case when selective activation of one neuronal population is desired. By beginning the infusion before beginning stimulation during time T1 to T2, the threshold for electrical activation of one population of neurons can be lowered or raised as needed. Another example would be if a precursor molecule, such as L-dopa, is infused to guard against depletion of the transmitter substance dopamine.
The stimulation might be applied periodically during the period of infusion either routinely or in response to sensor or patient generated demand as shown in FIG. 16B. Alternatively, stimulation could be applied continuously with infusion occurring periodically. Patient activation of either infusion or stimulation may occur as a result of an increase in symptoms being experienced by the patient.
Alternatively, the infusion of an agent to activate a neuronal population might be alternated with application of electrical stimulation of that same population, as shown in FIG. 16C.
It also is possible to infuse an agent that has an affect upon the neuron population that is not strictly connected in time with the electrical depolarization of the neurons. In this case, the time of application of stimulation and infusion may be completely asynchronous. Or an agent could be infused that diffuses beyond the effects of the electrical stimulation but still has an advantageous effect on the brain independent of the stimulation effects.
In those instances where a continuous infusion of liquid agent is effective, the infusion device may be replaced with a static device such as is described in U.S. Pat. No. 4,892,538 which is incorporated by reference. An example of a static device is a device having a semipermeable wall enclosing encapsulated cells capable of secreting the appropriate agent. Alternatively, an implantable device could consist of a polymeric insert with the agent embedded within or on the surface of the polymer in such a way as to be slowly eluted from the polymer over time. Such a device is described in U.S. Pat. No. 4,346,709 "Drug Delivery Devices Comprising Errodable Polymer and Errosion Rate Modifier", Edward Schmitt Inventor, Issued Aug. 31, 1982, incorporated by reference and in U.S. Pat. No. 5,330,768 "Long-term Sustained Release Preparation." Yoshiya Yamahira et. al. Inventors, Issued Sep. 27, 1988. These alternative techniques could be employed with or without the simultaneous application of open-loop or closed-loop stimulation in the aforementioned manner.
By using the foregoing techniques for simultaneous drug infusion and electrical stimulation, addictive disorders can be controlled with a degree of accuracy previously unattainable. Those skilled in that art will recognize that the preferred embodiments may be altered or amended without departing from the true spirit and scope of the invention, as defined in the accompanying claims.

Claims (9)

What is claimed is:
1. A method of using one or more drugs to therapeutically treat addictive disorders by means of an implantable pump and a catheter having a proximal end coupled to the pump and a discharge portion for infusing therapeutic dosages of the one or more drugs, as well as an electric signal generator and an implantable electrode having a proximal end and a stimulation portion, the method comprising the steps of:
surgically implanting the electrode so that the stimulation portion lies adjacent a predetermined stimulation site in brain tissue, the stimulation site chosen as a location that, when electrically stimulated, reduces symptoms of addictive disorders;
surgically implanting the catheter so that the discharge portion lies adjacent a predetermined infusion site in the brain tissue, the infusion site chosen as a location that, when therapeutic dosages of the one or more drugs are infused thereto, reduces symptoms of addictive disorders;
coupling the proximal end of the electrode to the signal generator;
operating the signal generator to stimulate the stimulation site;
operating the pump to discharge a predetermined dosage of the one or more drugs through the discharge portion of the catheter into the infusion site while the signal generator is stimulating the stimulation site, whereby addictive disorders are treated.
2. A method, as claimed in claim 1, wherein the stimulation site is selected from the group consisting of DORSAL MEDIAL THALAMUS, Pallido-thalamic axons (AL and LT), GPi/SNr, Subthalamic to pallidal fiber tracts, STN Nucleus, GPe, Neostriatum to Gpe fibers (i.e., border of nucleus), NUCLEUS ACCUMBENS and AMYGDALA.
3. A method, as claimed in claim 1, wherein the infusion site is selected from the group consisting of DORSAL MEDIAL THALAMUS, DORSAL MEDIAL THALAMUS, INTERNAL GLOBUS PALLIDUS (Gpi), SUBSTANTIA NIGRA RETICULATA (SNr), GPi/SNr, STN, EXTERNAL GLOBUS PALLIDUS (GPe), GPe, NUCLEUS ACCUMBENS, CENTRAL NUCLEUS OF THE AMYGDALA and LOCUS COERULEUS.
4. A method, as claimed in claim 1, wherein the one or more drugs is selected from the group consisting of GLUTAMATE ANTAGONIST, DEGRADING ENZYME, Anesthetic, ASPARTATE ANTAGONIST, GABA AGONIST, REUPTAKE BLOCKER, DEGRADING ENZYME BLOCKER, GLUTAMATE AGONIST, ASPARTATE AGONIST, GABA ANTAGONIST, DOPAMINE ANTAGONIST.
5. A method of using one or more drugs to therapeutically treat addictive disorders by means of an implantable pump and a catheter having a proximal end coupled to the pump and a discharge portion for infusing therapeutic dosages of the one or more drugs, the method comprising the steps of:
surgically implanting the catheter so that the discharge portion lies adjacent a predetermined infusion site in the brain tissue, the infusion site chosen as a location that, when therapeutic dosages of the one or more drugs are infused thereto, reduces symptoms of addictive disorders; and
operating the pump to discharge a predetermined dosage of the one or more drugs through the discharge portion of the catheter into the infusion site, whereby the addictive disorders is treated.
6. A method as claimed in claim 5 wherein the infusion site is selected from the group consisting of DORSAL MEDIAL THALAMUS, DORSAL MEDIAL THALAMUS, INTERNAL GLOBUS PALLIDUS (Gpi), SUBSTANTIA NIGRA RETICULATA (SNr), GPi/SNr, STN, EXTERNAL GLOBUS PALLIDUS (GPe), GPe, NUCLEUS ACCUMBENS, CENTRAL NUCLEUS OF THE AMYGDALA and LOCUS COERULEUS.
7. A method as claimed in claim 6 wherein the one or more drugs is selected from the group consisting of GLUTAMATE ANTAGONIST, DEGRADING ENZYME, Anesthetic, ASPARTATE ANTAGONIST, GABA AGONIST, REUPTAKE BLOCKER, DEGRADING ENZYME BLOCKER, GLUTAMATE AGONIST, ASPARTATE AGONIST, GABA ANTAGONIST, DOPAMINE ANTAGONIST.
8. A method of using electrical stimulation to therapeutically treat addictive disorders by means of a signal generator and an implantable electrode having a proximal end and a stimulation portion, the method comprising the steps of:
surgically implanting the electrode so that the stimulation portion lies adjacent a predetermined stimulation site in brain tissue;
coupling the proximal end of the electrode to the signal generator; and
operating the signal generator to stimulate the stimulation site, whereby the addictive disorders is treated.
9. A method, as claimed in claim 8, wherein the stimulation site is selected from the group consisting of DORSAL MEDIAL THALAMUS, Pallido-thalamic axons (AL and LT), GPi/SNr, Subthalamic to pallidal fiber tracts, STN Nucleus, GPe, Neostriatum to Gpe fibers (i.e., border of nucleus), NUCLEUS ACCUMBENS and AMYGDALA.
US09/303,182 1999-04-30 1999-04-30 Method of treating addiction by brain infusion Expired - Lifetime US6109269A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US09/303,182 US6109269A (en) 1999-04-30 1999-04-30 Method of treating addiction by brain infusion

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/303,182 US6109269A (en) 1999-04-30 1999-04-30 Method of treating addiction by brain infusion

Publications (1)

Publication Number Publication Date
US6109269A true US6109269A (en) 2000-08-29

Family

ID=23170880

Family Applications (1)

Application Number Title Priority Date Filing Date
US09/303,182 Expired - Lifetime US6109269A (en) 1999-04-30 1999-04-30 Method of treating addiction by brain infusion

Country Status (1)

Country Link
US (1) US6109269A (en)

Cited By (143)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001009897A1 (en) * 1999-07-30 2001-02-08 University Of Kentucky Research Foundation Method for storing and retrieving sequential information
US20020066457A1 (en) * 1999-07-30 2002-06-06 University Of Kentucky Neural network model for instruments that store and retrieve sequential information
US6420105B1 (en) 1999-08-13 2002-07-16 University Of Kentucky Research Foundation Method for analyzing molecular expression or function in an intact single cell
US6524300B2 (en) * 2000-01-03 2003-02-25 Angiodynamics, Inc. Infusion catheter with non-uniform drug delivery density
US6529774B1 (en) 2000-11-09 2003-03-04 Neuropace, Inc. Extradural leads, neurostimulator assemblies, and processes of using them for somatosensory and brain stimulation
US6569887B2 (en) 2001-08-24 2003-05-27 Dov Pharmaceuticals Inc. (−)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake
US6591138B1 (en) 2000-08-31 2003-07-08 Neuropace, Inc. Low frequency neurostimulator for the treatment of neurological disorders
WO2003059421A1 (en) * 2002-01-03 2003-07-24 Baxter International Inc. Method and apparatus for providing medical treatment therapy based on calculated demand
US6606521B2 (en) 2001-07-09 2003-08-12 Neuropace, Inc. Implantable medical lead
US20030181959A1 (en) * 2002-03-22 2003-09-25 Dobak John D. Wireless electric modulation of sympathetic nervous system
US20030181958A1 (en) * 2002-03-22 2003-09-25 Dobak John D. Electric modulation of sympathetic nervous system
US20030181954A1 (en) * 2001-12-24 2003-09-25 Rezai Ali R. Modulation of the brain to affect psychiatric disorders
US20030199944A1 (en) * 2002-02-08 2003-10-23 Chapin John K. Method and apparatus for guiding movement of a freely roaming animal through brain stimulation
US20040006091A1 (en) * 2002-03-01 2004-01-08 Kyle Donald J. Therapeutic agents useful for treating or preventing pain
EP1396233A1 (en) 2002-09-06 2004-03-10 Biosense, Inc. Positioning system for neurological procedures in the brain
US20040053914A1 (en) * 2002-05-02 2004-03-18 Parviz Gharagozloo Therapeutic agents useful for treating pain
US6713488B2 (en) 2000-03-15 2004-03-30 Sadee Wolfgang Neutral antagonists and use thereof in treating drug abuse
US20040106625A1 (en) * 2002-06-28 2004-06-03 Kyle Donald J. Therapeutic agents useful for treating pain
US20040127501A1 (en) * 2002-09-24 2004-07-01 Zhengming Chen Therapeutic agents useful for treating pain
US20040186111A1 (en) * 2002-12-24 2004-09-23 Qun Sun Therapeutic agents useful for treating pain
US20040230255A1 (en) * 2002-03-22 2004-11-18 Dobak John D. Splanchnic nerve stimulation for treatment of obesity
US20040235853A1 (en) * 2002-07-26 2004-11-25 Kyle Donald J. Therapeutic agents useful for treating pain
US20050010262A1 (en) * 2002-02-01 2005-01-13 Ali Rezai Modulation of the pain circuitry to affect chronic pain
US20050065575A1 (en) * 2002-09-13 2005-03-24 Dobak John D. Dynamic nerve stimulation for treatment of disorders
US20050214217A1 (en) * 2004-03-26 2005-09-29 Mai Levite Methods of and pharmaceutical compositions for modulating T-lymphocyte adhesion, migration, gene expression and function by Glutamate and analogs thereof
US20050240242A1 (en) * 1998-08-05 2005-10-27 Dilorenzo Daniel J Closed-loop feedback-driven neuromodulation
US20060058856A1 (en) * 2004-09-14 2006-03-16 Neuropace, Inc. Responsive therapy for psychiatric disorders
US20060079943A1 (en) * 2004-08-31 2006-04-13 Narciso Hugh L Jr Devices and methods for gynecologic hormone modulation in mammals
US20060100263A1 (en) * 2004-11-05 2006-05-11 Anthony Basile Antipyretic compositions and methods
US7071335B2 (en) 2002-02-01 2006-07-04 Euro-Celtique S.A. 2-pyridinyl-1-piperazine therapeutic agents useful for treating pain
US20060173064A1 (en) * 2001-08-24 2006-08-03 Lippa Arnold S (-)-1-(3,4-Dichlorophenyl)-3-azabi cyclo[3.1.0]hexane, compositions thereof, and uses for treating alcohol-related disorders
US20060190053A1 (en) * 2002-03-22 2006-08-24 Dobak John D Iii Neural stimulation for treatment of metabolic syndrome and type 2 diabetes
US20060235055A1 (en) * 2003-07-03 2006-10-19 Kyle Donald J Therapeutic agents useful for treating pain
US7157462B2 (en) 2002-09-24 2007-01-02 Euro-Celtique S.A. Therapeutic agents useful for treating pain
US20070027498A1 (en) * 2005-07-29 2007-02-01 Cyberonics, Inc. Selective nerve stimulation for the treatment of eating disorders
US20070027482A1 (en) * 2005-07-27 2007-02-01 Cyberonics, Inc. Cranial nerve stimulation to treat a vocal cord disorder
US20070027499A1 (en) * 2005-07-29 2007-02-01 Cyberonics, Inc. Neurostimulation device for treating mood disorders
US20070043100A1 (en) * 2005-08-16 2007-02-22 Hagen Eric J Novel polymorphs of azabicyclohexane
US7209787B2 (en) 1998-08-05 2007-04-24 Bioneuronics Corporation Apparatus and method for closed-loop intracranial stimulation for optimal control of neurological disease
US7242984B2 (en) 1998-08-05 2007-07-10 Neurovista Corporation Apparatus and method for closed-loop intracranial stimulation for optimal control of neurological disease
US20070162086A1 (en) * 1998-08-05 2007-07-12 Bioneuronics Corporation Monitoring efficacy of neural modulation therapy
US20070203521A1 (en) * 2002-03-22 2007-08-30 Leptos Biomedical, Inc. Nerve stimulation for treatment of obesity, metabolic syndrome, and type 2 diabetes
US20070225773A1 (en) * 2005-09-28 2007-09-27 Yang Shen Implantable transcranial pulse generator having a collapsible portion
US7277758B2 (en) 1998-08-05 2007-10-02 Neurovista Corporation Methods and systems for predicting future symptomatology in a patient suffering from a neurological or psychiatric disorder
US7324851B1 (en) 1998-08-05 2008-01-29 Neurovista Corporation Closed-loop feedback-driven neuromodulation
US20080033511A1 (en) * 2002-03-22 2008-02-07 Leptos Biomedical, Inc. Dynamic nerve stimulation employing frequency modulation
US20080045725A1 (en) * 2006-04-28 2008-02-21 Murry Jerry A Process For The Synthesis of (+) And (-)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane
US20080125829A1 (en) * 2004-04-30 2008-05-29 Advanced Neuromodulation Systems, Inc. Method of treating mood disorders and/or anxiety disorders by brain stimulation
US7403820B2 (en) 1998-08-05 2008-07-22 Neurovista Corporation Closed-loop feedback-driven neuromodulation
US20080269348A1 (en) * 2006-11-07 2008-10-30 Phil Skolnick Novel Arylbicyclo[3.1.0]Hexylamines And Methods And Compositions For Their Preparation And Use
US20080293822A1 (en) * 2006-11-07 2008-11-27 Phil Skolnick Novel Arylbicyclo[3.1.0]Hexylamines And Methods And Compositions For Their Preparation And Use
US20090069374A1 (en) * 2007-06-06 2009-03-12 Phil Skolnick Novel 1-Heteroaryl-3-Azabicyclo[3.1.0]Hexanes, Methods For Their Preparation And Their Use As Medicaments
US20090118777A1 (en) * 2007-08-09 2009-05-07 Kobi Iki Efferent and afferent splanchnic nerve stimulation
US20090129856A1 (en) * 2007-11-21 2009-05-21 Michael Gomez Quick-release system
US7555344B2 (en) 2005-10-28 2009-06-30 Cyberonics, Inc. Selective neurostimulation for treating epilepsy
US20090233978A1 (en) * 2005-07-27 2009-09-17 Phil Skolnick Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders
US20090259279A1 (en) * 2002-03-22 2009-10-15 Dobak Iii John D Splanchnic nerve stimulation for treatment of obesity
US7657310B2 (en) 2006-01-26 2010-02-02 Cyberonics, Inc. Treatment of reproductive endocrine disorders by vagus nerve stimulation
US20100057160A1 (en) * 2004-10-21 2010-03-04 Advanced Neuromodulation Systems, Inc. Stimulation of the amygdalohippocampal complex to treat neurological conditions
US7676263B2 (en) 2006-06-23 2010-03-09 Neurovista Corporation Minimally invasive system for selecting patient-specific therapy parameters
US7706874B2 (en) 2005-07-28 2010-04-27 Cyberonics, Inc. Stimulating cranial nerve to treat disorders associated with the thyroid gland
US7706875B2 (en) 2007-01-25 2010-04-27 Cyberonics, Inc. Modulation of drug effects by vagus nerve stimulation
US7747325B2 (en) 1998-08-05 2010-06-29 Neurovista Corporation Systems and methods for monitoring a patient's neurological disease state
US7801601B2 (en) 2006-01-27 2010-09-21 Cyberonics, Inc. Controlling neuromodulation using stimulus modalities
US20100268297A1 (en) * 2009-02-24 2010-10-21 Hans Neisz Duodenal Stimulation To Induce Satiety
US7974696B1 (en) 1998-08-05 2011-07-05 Dilorenzo Biomedical, Llc Closed-loop autonomic neuromodulation for optimal control of neurological and metabolic disease
US20110171325A1 (en) * 2006-08-30 2011-07-14 Andres Lozano Systems and Methods for Treating Pain Using Brain Stimulation
US8036736B2 (en) 2007-03-21 2011-10-11 Neuro Vista Corporation Implantable systems and methods for identifying a contra-ictal condition in a subject
US8295926B2 (en) 2006-06-02 2012-10-23 Advanced Neuromodulation Systems, Inc. Dynamic nerve stimulation in combination with other eating disorder treatment modalities
US8295934B2 (en) 2006-11-14 2012-10-23 Neurovista Corporation Systems and methods of reducing artifact in neurological stimulation systems
US8321030B2 (en) 2009-04-20 2012-11-27 Advanced Neuromodulation Systems, Inc. Esophageal activity modulated obesity therapy
US8340772B2 (en) 2009-05-08 2012-12-25 Advanced Neuromodulation Systems, Inc. Brown adipose tissue utilization through neuromodulation
US8588933B2 (en) 2009-01-09 2013-11-19 Cyberonics, Inc. Medical lead termination sleeve for implantable medical devices
US8660647B2 (en) 2005-07-28 2014-02-25 Cyberonics, Inc. Stimulating cranial nerve to treat pulmonary disorder
US8700163B2 (en) 2005-03-04 2014-04-15 Cyberonics, Inc. Cranial nerve stimulation for treatment of substance addiction
US8725243B2 (en) 2005-12-28 2014-05-13 Cyberonics, Inc. Methods and systems for recommending an appropriate pharmacological treatment to a patient for managing epilepsy and other neurological disorders
US8762065B2 (en) 1998-08-05 2014-06-24 Cyberonics, Inc. Closed-loop feedback-driven neuromodulation
US8774937B2 (en) 2009-12-01 2014-07-08 Ecole Polytechnique Federale De Lausanne Microfabricated surface neurostimulation device and methods of making and using the same
US8786624B2 (en) 2009-06-02 2014-07-22 Cyberonics, Inc. Processing for multi-channel signals
US8788042B2 (en) 2008-07-30 2014-07-22 Ecole Polytechnique Federale De Lausanne (Epfl) Apparatus and method for optimized stimulation of a neurological target
US8788064B2 (en) 2008-11-12 2014-07-22 Ecole Polytechnique Federale De Lausanne Microfabricated neurostimulation device
US8849390B2 (en) 2008-12-29 2014-09-30 Cyberonics, Inc. Processing for multi-channel signals
US8868172B2 (en) 2005-12-28 2014-10-21 Cyberonics, Inc. Methods and systems for recommending an appropriate action to a patient for managing epilepsy and other neurological disorders
US9042988B2 (en) 1998-08-05 2015-05-26 Cyberonics, Inc. Closed-loop vagus nerve stimulation
US9133159B2 (en) 2007-06-06 2015-09-15 Neurovance, Inc. 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
US9259591B2 (en) 2007-12-28 2016-02-16 Cyberonics, Inc. Housing for an implantable medical device
US9375573B2 (en) 1998-08-05 2016-06-28 Cyberonics, Inc. Systems and methods for monitoring a patient's neurological disease state
US9393204B2 (en) 2002-07-31 2016-07-19 Ebi Life Sciences, Inc. Methods and compositions employing bicifadine for treating disability or functional impairment associated with acute pain, chronic pain, or neuropathic disorders
US9403011B2 (en) 2014-08-27 2016-08-02 Aleva Neurotherapeutics Leadless neurostimulator
US9415222B2 (en) 1998-08-05 2016-08-16 Cyberonics, Inc. Monitoring an epilepsy disease state with a supervisory module
US9474894B2 (en) 2014-08-27 2016-10-25 Aleva Neurotherapeutics Deep brain stimulation lead
US9501829B2 (en) 2011-03-29 2016-11-22 Boston Scientific Neuromodulation Corporation System and method for atlas registration
US9526902B2 (en) 2008-05-15 2016-12-27 Boston Scientific Neuromodulation Corporation VOA generation system and method using a fiber specific analysis
US9538949B2 (en) 2010-09-28 2017-01-10 Masimo Corporation Depth of consciousness monitor including oximeter
US9545510B2 (en) 2008-02-12 2017-01-17 Intelect Medical, Inc. Directional lead assembly with electrode anchoring prongs
US9549708B2 (en) 2010-04-01 2017-01-24 Ecole Polytechnique Federale De Lausanne Device for interacting with neurological tissue and methods of making and using the same
US9561380B2 (en) 2012-08-28 2017-02-07 Boston Scientific Neuromodulation Corporation Point-and-click programming for deep brain stimulation using real-time monopolar review trendlines
US9592389B2 (en) 2011-05-27 2017-03-14 Boston Scientific Neuromodulation Corporation Visualization of relevant stimulation leadwire electrodes relative to selected stimulation information
WO2017044967A1 (en) * 2015-09-11 2017-03-16 Taca Jr Dr Arturo C Treatment of addiction and dependency
US9604067B2 (en) 2012-08-04 2017-03-28 Boston Scientific Neuromodulation Corporation Techniques and methods for storing and transferring registration, atlas, and lead information between medical devices
US9622675B2 (en) 2007-01-25 2017-04-18 Cyberonics, Inc. Communication error alerting in an epilepsy monitoring system
US9643019B2 (en) 2010-02-12 2017-05-09 Cyberonics, Inc. Neurological monitoring and alerts
US9760688B2 (en) 2004-07-07 2017-09-12 Cleveland Clinic Foundation Method and device for displaying predicted volume of influence
US9776003B2 (en) 2009-12-02 2017-10-03 The Cleveland Clinic Foundation Reversing cognitive-motor impairments in patients having a neuro-degenerative disease using a computational modeling approach to deep brain stimulation programming
US9788744B2 (en) 2007-07-27 2017-10-17 Cyberonics, Inc. Systems for monitoring brain activity and patient advisory device
US9792412B2 (en) 2012-11-01 2017-10-17 Boston Scientific Neuromodulation Corporation Systems and methods for VOA model generation and use
EP3151913A4 (en) * 2014-06-03 2017-11-15 Ridder, Dirk, De Systems and methods of treating a neurological disorder in a patient
US9867989B2 (en) 2010-06-14 2018-01-16 Boston Scientific Neuromodulation Corporation Programming interface for spinal cord neuromodulation
US9898656B2 (en) 2007-01-25 2018-02-20 Cyberonics, Inc. Systems and methods for identifying a contra-ictal condition in a subject
US9925376B2 (en) 2014-08-27 2018-03-27 Aleva Neurotherapeutics Treatment of autoimmune diseases with deep brain stimulation
US9925382B2 (en) 2011-08-09 2018-03-27 Boston Scientific Neuromodulation Corporation Systems and methods for stimulation-related volume analysis, creation, and sharing
US9956419B2 (en) 2015-05-26 2018-05-01 Boston Scientific Neuromodulation Corporation Systems and methods for analyzing electrical stimulation and selecting or manipulating volumes of activation
US9959388B2 (en) 2014-07-24 2018-05-01 Boston Scientific Neuromodulation Corporation Systems, devices, and methods for providing electrical stimulation therapy feedback
US9974959B2 (en) 2014-10-07 2018-05-22 Boston Scientific Neuromodulation Corporation Systems, devices, and methods for electrical stimulation using feedback to adjust stimulation parameters
US10071249B2 (en) 2015-10-09 2018-09-11 Boston Scientific Neuromodulation Corporation System and methods for clinical effects mapping for directional stimulation leads
US10154815B2 (en) 2014-10-07 2018-12-18 Masimo Corporation Modular physiological sensors
US10265528B2 (en) 2014-07-30 2019-04-23 Boston Scientific Neuromodulation Corporation Systems and methods for electrical stimulation-related patient population volume analysis and use
US10272247B2 (en) 2014-07-30 2019-04-30 Boston Scientific Neuromodulation Corporation Systems and methods for stimulation-related volume analysis, creation, and sharing with integrated surgical planning and stimulation programming
US10350404B2 (en) 2016-09-02 2019-07-16 Boston Scientific Neuromodulation Corporation Systems and methods for visualizing and directing stimulation of neural elements
US10360511B2 (en) 2005-11-28 2019-07-23 The Cleveland Clinic Foundation System and method to estimate region of tissue activation
US10434302B2 (en) 2008-02-11 2019-10-08 Intelect Medical, Inc. Directional electrode devices with locating features
US10441800B2 (en) 2015-06-29 2019-10-15 Boston Scientific Neuromodulation Corporation Systems and methods for selecting stimulation parameters by targeting and steering
US10589104B2 (en) 2017-01-10 2020-03-17 Boston Scientific Neuromodulation Corporation Systems and methods for creating stimulation programs based on user-defined areas or volumes
US10603498B2 (en) 2016-10-14 2020-03-31 Boston Scientific Neuromodulation Corporation Systems and methods for closed-loop determination of stimulation parameter settings for an electrical simulation system
US10625082B2 (en) 2017-03-15 2020-04-21 Boston Scientific Neuromodulation Corporation Visualization of deep brain stimulation efficacy
US10716505B2 (en) 2017-07-14 2020-07-21 Boston Scientific Neuromodulation Corporation Systems and methods for estimating clinical effects of electrical stimulation
US10716942B2 (en) 2016-04-25 2020-07-21 Boston Scientific Neuromodulation Corporation System and methods for directional steering of electrical stimulation
US10776456B2 (en) 2016-06-24 2020-09-15 Boston Scientific Neuromodulation Corporation Systems and methods for visual analytics of clinical effects
US10780283B2 (en) 2015-05-26 2020-09-22 Boston Scientific Neuromodulation Corporation Systems and methods for analyzing electrical stimulation and selecting or manipulating volumes of activation
US10780282B2 (en) 2016-09-20 2020-09-22 Boston Scientific Neuromodulation Corporation Systems and methods for steering electrical stimulation of patient tissue and determining stimulation parameters
US10792501B2 (en) 2017-01-03 2020-10-06 Boston Scientific Neuromodulation Corporation Systems and methods for selecting MRI-compatible stimulation parameters
US10960214B2 (en) 2017-08-15 2021-03-30 Boston Scientific Neuromodulation Corporation Systems and methods for controlling electrical stimulation using multiple stimulation fields
US10966620B2 (en) 2014-05-16 2021-04-06 Aleva Neurotherapeutics Sa Device for interacting with neurological tissue and methods of making and using the same
US11160981B2 (en) 2015-06-29 2021-11-02 Boston Scientific Neuromodulation Corporation Systems and methods for selecting stimulation parameters based on stimulation target region, effects, or side effects
US11266830B2 (en) 2018-03-02 2022-03-08 Aleva Neurotherapeutics Neurostimulation device
US11285329B2 (en) 2018-04-27 2022-03-29 Boston Scientific Neuromodulation Corporation Systems and methods for visualizing and programming electrical stimulation
US11298553B2 (en) 2018-04-27 2022-04-12 Boston Scientific Neuromodulation Corporation Multi-mode electrical stimulation systems and methods of making and using
US11311718B2 (en) 2014-05-16 2022-04-26 Aleva Neurotherapeutics Sa Device for interacting with neurological tissue and methods of making and using the same
US11357986B2 (en) 2017-04-03 2022-06-14 Boston Scientific Neuromodulation Corporation Systems and methods for estimating a volume of activation using a compressed database of threshold values
US11406317B2 (en) 2007-12-28 2022-08-09 Livanova Usa, Inc. Method for detecting neurological and clinical manifestations of a seizure
US12042481B2 (en) 2011-07-30 2024-07-23 Otsuka America Pharmaceutical, Inc. Use of (1R,5S)-(+)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane in the treatment of conditions affected by monoamine neurotransmitters
US12403313B2 (en) 2021-06-15 2025-09-02 Boston Scientific Neuromodulation Corporation Methods and systems for estimating neural activation by stimulation using a stimulation system
US12403315B2 (en) 2021-04-27 2025-09-02 Boston Scientific Neuromodulation Corporation Systems and methods for automated programming of electrical stimulation

Citations (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3887699A (en) * 1969-03-24 1975-06-03 Seymour Yolles Biodegradable polymeric article for dispensing drugs
US3946745A (en) * 1973-03-22 1976-03-30 Biopulse Company Limited Apparatus for generating positive and negative electric pulses for application to a living body for therapeutic purposes
US4346709A (en) * 1980-11-10 1982-08-31 Alza Corporation Drug delivery devices comprising erodible polymer and erosion rate modifier
US4646744A (en) * 1984-06-29 1987-03-03 Zion Foundation Method and treatment with transcranially applied electrical signals
US4692147A (en) * 1980-04-02 1987-09-08 Medtronic, Inc. Drug administration device
US4841973A (en) * 1987-09-21 1989-06-27 Stecker Harold D Electrical stimulators
US4865048A (en) * 1987-12-31 1989-09-12 Eckerson Harold D Method and apparatus for drug free neurostimulation
US4892538A (en) * 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5039680A (en) * 1987-07-11 1991-08-13 Sandoz Ltd. New use of 5HT-3 antagonists in preventing or reducing dependency on dependency-inducing agents
US5075341A (en) * 1989-12-01 1991-12-24 The Mclean Hospital Corporation Treatment for cocaine abuse
US5084007A (en) * 1989-08-11 1992-01-28 Malin David H Method for chemical promotion of the effects of low current transcranial electrostimulation
US5119832A (en) * 1989-07-11 1992-06-09 Ravi Xavier Epidural catheter with nerve stimulators
US5198459A (en) * 1987-07-11 1993-03-30 Sandoz Ltd. Use of 5HT-3 antagonists in preventing or reducing dependency on dependency-inducing agents
US5232934A (en) * 1992-07-17 1993-08-03 Warner-Lambert Co. Method for the treatment of psychomotor stimulant addiction
US5259387A (en) * 1991-09-09 1993-11-09 Quinton Instrument Company ECG muscle artifact filter system
US5330768A (en) * 1991-07-05 1994-07-19 Massachusetts Institute Of Technology Controlled drug delivery using polymer/pluronic blends
US5415629A (en) * 1993-09-15 1995-05-16 Henley; Julian L. Programmable apparatus for the transdermal delivery of drugs and method
US5423877A (en) * 1992-05-04 1995-06-13 David C. Mackey Method and device for acute pain management by simultaneous spinal cord electrical stimulation and drug infusion
US5458631A (en) * 1989-01-06 1995-10-17 Xavier; Ravi Implantable catheter with electrical pulse nerve stimulators and drug delivery system
US5458629A (en) * 1994-02-18 1995-10-17 Medtronic, Inc. Implantable lead ring electrode and method of making
US5458625A (en) * 1994-05-04 1995-10-17 Kendall; Donald E. Transcutaneous nerve stimulation device and method for using same
US5556838A (en) * 1993-01-28 1996-09-17 Virginia Commonwealth University Inhibiting the development of tolerance to and/or dependence on an addictive substance
US5574052A (en) * 1986-03-17 1996-11-12 Robert J. Schaap Agonist-antagonist combination to reduce the use of nicotine and other drugs
US5593432A (en) * 1993-06-23 1997-01-14 Neuroware Therapy International, Inc. Method for neurostimulation for pain alleviation
US5711316A (en) * 1996-04-30 1998-01-27 Medtronic, Inc. Method of treating movement disorders by brain infusion
US5762925A (en) * 1994-11-03 1998-06-09 Sagen; Jacqueline Preventing opiate tolerance by cellular implantation

Patent Citations (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3887699A (en) * 1969-03-24 1975-06-03 Seymour Yolles Biodegradable polymeric article for dispensing drugs
US3946745A (en) * 1973-03-22 1976-03-30 Biopulse Company Limited Apparatus for generating positive and negative electric pulses for application to a living body for therapeutic purposes
US4692147A (en) * 1980-04-02 1987-09-08 Medtronic, Inc. Drug administration device
US4346709A (en) * 1980-11-10 1982-08-31 Alza Corporation Drug delivery devices comprising erodible polymer and erosion rate modifier
US4646744A (en) * 1984-06-29 1987-03-03 Zion Foundation Method and treatment with transcranially applied electrical signals
US5574052A (en) * 1986-03-17 1996-11-12 Robert J. Schaap Agonist-antagonist combination to reduce the use of nicotine and other drugs
US5198459A (en) * 1987-07-11 1993-03-30 Sandoz Ltd. Use of 5HT-3 antagonists in preventing or reducing dependency on dependency-inducing agents
US5039680A (en) * 1987-07-11 1991-08-13 Sandoz Ltd. New use of 5HT-3 antagonists in preventing or reducing dependency on dependency-inducing agents
US4841973A (en) * 1987-09-21 1989-06-27 Stecker Harold D Electrical stimulators
US4892538A (en) * 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US4865048A (en) * 1987-12-31 1989-09-12 Eckerson Harold D Method and apparatus for drug free neurostimulation
US5458631A (en) * 1989-01-06 1995-10-17 Xavier; Ravi Implantable catheter with electrical pulse nerve stimulators and drug delivery system
US5119832A (en) * 1989-07-11 1992-06-09 Ravi Xavier Epidural catheter with nerve stimulators
US5084007A (en) * 1989-08-11 1992-01-28 Malin David H Method for chemical promotion of the effects of low current transcranial electrostimulation
US5075341A (en) * 1989-12-01 1991-12-24 The Mclean Hospital Corporation Treatment for cocaine abuse
US5330768A (en) * 1991-07-05 1994-07-19 Massachusetts Institute Of Technology Controlled drug delivery using polymer/pluronic blends
US5259387A (en) * 1991-09-09 1993-11-09 Quinton Instrument Company ECG muscle artifact filter system
US5423877A (en) * 1992-05-04 1995-06-13 David C. Mackey Method and device for acute pain management by simultaneous spinal cord electrical stimulation and drug infusion
US5232934A (en) * 1992-07-17 1993-08-03 Warner-Lambert Co. Method for the treatment of psychomotor stimulant addiction
US5556838A (en) * 1993-01-28 1996-09-17 Virginia Commonwealth University Inhibiting the development of tolerance to and/or dependence on an addictive substance
US5593432A (en) * 1993-06-23 1997-01-14 Neuroware Therapy International, Inc. Method for neurostimulation for pain alleviation
US5415629A (en) * 1993-09-15 1995-05-16 Henley; Julian L. Programmable apparatus for the transdermal delivery of drugs and method
US5538503A (en) * 1993-09-15 1996-07-23 Henley; Julian L. Programmable apparatus for reducing substance dependency in transdermal drug delivery
US5458629A (en) * 1994-02-18 1995-10-17 Medtronic, Inc. Implantable lead ring electrode and method of making
US5458625A (en) * 1994-05-04 1995-10-17 Kendall; Donald E. Transcutaneous nerve stimulation device and method for using same
US5762925A (en) * 1994-11-03 1998-06-09 Sagen; Jacqueline Preventing opiate tolerance by cellular implantation
US5711316A (en) * 1996-04-30 1998-01-27 Medtronic, Inc. Method of treating movement disorders by brain infusion

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
Craig G. van Horne, Spencer Bement, Barry J. Hoffer, Greg A. Gerhardt, "Multichannel semiconductor-based electrodes for in vivo electrochemical and electrophysiological studies in rat CNS" Neuroscience Letters, 120(1990) 249-252.
Craig G. van Horne, Spencer Bement, Barry J. Hoffer, Greg A. Gerhardt, Multichannel semiconductor based electrodes for in vivo electrochemical and electrophysiological studies in rat CNS Neuroscience Letters , 120(1990) 249 252. *
George F. Koob, Drugs of abuse: anatomy, pharmacology and function of reward pathways. TiPS May 1992 vol. 13. *
George F. Koob, Drugs of abuse: anatomy, pharmacology and function of reward pathways. TiPS--May 1992 vol. 13.
Harris Corporation Model CDP 1878 frequency generator. *
Medtronic Itrel II Implantable Pulse Generator (IPG) Model 7424. *
Olds & Milner, "Positive reinforcement produced by electrical stimulation of septal area and other regions of rat brain" J. Comp Physiol Psychol 47:419-427, 1954.
Olds & Milner, Positive reinforcement produced by electrical stimulation of septal area and other regions of rat brain J. Comp Physiol Psychol 47:419 427, 1954. *

Cited By (289)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7623928B2 (en) 1998-08-05 2009-11-24 Neurovista Corporation Controlling a subject's susceptibility to a seizure
US7277758B2 (en) 1998-08-05 2007-10-02 Neurovista Corporation Methods and systems for predicting future symptomatology in a patient suffering from a neurological or psychiatric disorder
US7209787B2 (en) 1998-08-05 2007-04-24 Bioneuronics Corporation Apparatus and method for closed-loop intracranial stimulation for optimal control of neurological disease
US7231254B2 (en) 1998-08-05 2007-06-12 Bioneuronics Corporation Closed-loop feedback-driven neuromodulation
US20050240242A1 (en) * 1998-08-05 2005-10-27 Dilorenzo Daniel J Closed-loop feedback-driven neuromodulation
US7242984B2 (en) 1998-08-05 2007-07-10 Neurovista Corporation Apparatus and method for closed-loop intracranial stimulation for optimal control of neurological disease
US7974696B1 (en) 1998-08-05 2011-07-05 Dilorenzo Biomedical, Llc Closed-loop autonomic neuromodulation for optimal control of neurological and metabolic disease
US7930035B2 (en) 1998-08-05 2011-04-19 Neurovista Corporation Providing output indicative of subject's disease state
US7853329B2 (en) 1998-08-05 2010-12-14 Neurovista Corporation Monitoring efficacy of neural modulation therapy
US7747325B2 (en) 1998-08-05 2010-06-29 Neurovista Corporation Systems and methods for monitoring a patient's neurological disease state
US8762065B2 (en) 1998-08-05 2014-06-24 Cyberonics, Inc. Closed-loop feedback-driven neuromodulation
US8781597B2 (en) 1998-08-05 2014-07-15 Cyberonics, Inc. Systems for monitoring a patient's neurological disease state
US20070162086A1 (en) * 1998-08-05 2007-07-12 Bioneuronics Corporation Monitoring efficacy of neural modulation therapy
US9042988B2 (en) 1998-08-05 2015-05-26 Cyberonics, Inc. Closed-loop vagus nerve stimulation
US7324851B1 (en) 1998-08-05 2008-01-29 Neurovista Corporation Closed-loop feedback-driven neuromodulation
US9113801B2 (en) 1998-08-05 2015-08-25 Cyberonics, Inc. Methods and systems for continuous EEG monitoring
US9320900B2 (en) 1998-08-05 2016-04-26 Cyberonics, Inc. Methods and systems for determining subject-specific parameters for a neuromodulation therapy
US9375573B2 (en) 1998-08-05 2016-06-28 Cyberonics, Inc. Systems and methods for monitoring a patient's neurological disease state
US9415222B2 (en) 1998-08-05 2016-08-16 Cyberonics, Inc. Monitoring an epilepsy disease state with a supervisory module
US7403820B2 (en) 1998-08-05 2008-07-22 Neurovista Corporation Closed-loop feedback-driven neuromodulation
US9421373B2 (en) 1998-08-05 2016-08-23 Cyberonics, Inc. Apparatus and method for closed-loop intracranial stimulation for optimal control of neurological disease
US7643354B2 (en) 1999-07-30 2010-01-05 University Of Kentucky Research Foundation Neural network model for instruments that store and retrieve sequential information
US6354298B1 (en) 1999-07-30 2002-03-12 University Of Kentucky Research Foundation Method for storing and retrieving sequential information
WO2001009897A1 (en) * 1999-07-30 2001-02-08 University Of Kentucky Research Foundation Method for storing and retrieving sequential information
US20020066457A1 (en) * 1999-07-30 2002-06-06 University Of Kentucky Neural network model for instruments that store and retrieve sequential information
US6420105B1 (en) 1999-08-13 2002-07-16 University Of Kentucky Research Foundation Method for analyzing molecular expression or function in an intact single cell
US6524300B2 (en) * 2000-01-03 2003-02-25 Angiodynamics, Inc. Infusion catheter with non-uniform drug delivery density
US6713488B2 (en) 2000-03-15 2004-03-30 Sadee Wolfgang Neutral antagonists and use thereof in treating drug abuse
US9033861B2 (en) 2000-08-31 2015-05-19 Neuropace, Inc. Low frequency neurostimulator for the treatment of neurological disorders
US9352168B2 (en) 2000-08-31 2016-05-31 Neuropace, Inc. Low frequency neurostimulator for the treatment of neurological disorders
US10279191B2 (en) 2000-08-31 2019-05-07 Neuropace, Inc. Low frequency neurostimulator for the treatment of neurological disorders
US6591138B1 (en) 2000-08-31 2003-07-08 Neuropace, Inc. Low frequency neurostimulator for the treatment of neurological disorders
US20090318747A1 (en) * 2000-08-31 2009-12-24 Neuropace, Inc. Low Frequency Neurostimulator for the Treatment of Neurological Disorders
US9694195B2 (en) 2000-08-31 2017-07-04 Neuropace, Inc. Low frequency neurostimulator for the treatment of neurological disorders
US6529774B1 (en) 2000-11-09 2003-03-04 Neuropace, Inc. Extradural leads, neurostimulator assemblies, and processes of using them for somatosensory and brain stimulation
US6606521B2 (en) 2001-07-09 2003-08-12 Neuropace, Inc. Implantable medical lead
US20030181508A1 (en) * 2001-08-24 2003-09-25 Dov Pharmaceuticals, Inc. (-)-1-(3,4-DichlorophenyI)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor
US20040157869A1 (en) * 2001-08-24 2004-08-12 Dov Pharmaceutical, Inc. (-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor
US7041835B2 (en) 2001-08-24 2006-05-09 Dor Pharmaceutical, Inc. (−)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor
US20040157908A1 (en) * 2001-08-24 2004-08-12 Dov Pharmaceutical, Inc. (-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor
US20040157870A1 (en) * 2001-08-24 2004-08-12 Lippa Arnold Stan (-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor
US7081471B2 (en) 2001-08-24 2006-07-25 Dov Pharmaceutical, Inc. (-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor
US20060173064A1 (en) * 2001-08-24 2006-08-03 Lippa Arnold S (-)-1-(3,4-Dichlorophenyl)-3-azabi cyclo[3.1.0]hexane, compositions thereof, and uses for treating alcohol-related disorders
US6569887B2 (en) 2001-08-24 2003-05-27 Dov Pharmaceuticals Inc. (−)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake
US7098230B2 (en) 2001-08-24 2006-08-29 Dov Pharmaceutical, Inc. (-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor
US6716868B2 (en) 2001-08-24 2004-04-06 Dov Pharmaceutical Inc (-)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor
US20030181954A1 (en) * 2001-12-24 2003-09-25 Rezai Ali R. Modulation of the brain to affect psychiatric disorders
US7623927B2 (en) 2001-12-24 2009-11-24 The Cleveland Clinic Foundation Modulation of the brain to affect psychiatric disorders
WO2003059421A1 (en) * 2002-01-03 2003-07-24 Baxter International Inc. Method and apparatus for providing medical treatment therapy based on calculated demand
US8545435B2 (en) 2002-01-03 2013-10-01 Baxter International, Inc. Method and apparatus for providing medical treatment therapy based on calculated demand
US20050010262A1 (en) * 2002-02-01 2005-01-13 Ali Rezai Modulation of the pain circuitry to affect chronic pain
EP2033951A2 (en) 2002-02-01 2009-03-11 Euro-Celtique S.A. 2-Piperazine-pyridines useful for treating pain
US7071335B2 (en) 2002-02-01 2006-07-04 Euro-Celtique S.A. 2-pyridinyl-1-piperazine therapeutic agents useful for treating pain
US7256193B2 (en) 2002-02-01 2007-08-14 Euro-Celtique S.A. Therapeutic agents useful for treating pain
US20030199944A1 (en) * 2002-02-08 2003-10-23 Chapin John K. Method and apparatus for guiding movement of a freely roaming animal through brain stimulation
US7970476B2 (en) 2002-02-08 2011-06-28 The Research Foundation Of The State University Of New York Method and apparatus for guiding movement of a freely roaming animal through brain stimulation
EP1471971A4 (en) * 2002-02-08 2007-01-03 John K Chapin Method and apparatus for guiding movement of a freely roaming animal through brain stimulation
US20040006091A1 (en) * 2002-03-01 2004-01-08 Kyle Donald J. Therapeutic agents useful for treating or preventing pain
US6974818B2 (en) 2002-03-01 2005-12-13 Euro-Celtique S.A. 1,2,5-thiadiazol-3-YL-piperazine therapeutic agents useful for treating pain
US7342017B2 (en) 2002-03-01 2008-03-11 Euro-Celtique S.A. 1,2,5-Thiadiazol-3-yl-piperazine therapeutic agents useful for treating pain, depression and anxiety
US20060074090A1 (en) * 2002-03-01 2006-04-06 Euro-Celtique S.A. 1,2,5-Thiadiazol-3-yl-piperazine therapeutic agents useful for treating pain, depression and anxiety
US20100145408A1 (en) * 2002-03-22 2010-06-10 Dobak Iii John D Splanchnic Nerve Stimulation For Treatment of Obesity
US20070219596A1 (en) * 2002-03-22 2007-09-20 Leptos Biomedical, Inc. Electric modulation of sympathetic nervous sytem
US20070203521A1 (en) * 2002-03-22 2007-08-30 Leptos Biomedical, Inc. Nerve stimulation for treatment of obesity, metabolic syndrome, and type 2 diabetes
US20070225768A1 (en) * 2002-03-22 2007-09-27 Leptos Biomedical, Inc. Electric modulation of sympathetic nervous system
US8340760B2 (en) 2002-03-22 2012-12-25 Advanced Neuromodulation Systems, Inc. Electric modulation of sympathetic nervous system
US8024035B2 (en) 2002-03-22 2011-09-20 Advanced Neuromodulation Systems, Inc. Electric modulation of sympathetic nervous system
US20110178568A1 (en) * 2002-03-22 2011-07-21 Advanced Neuromodulation Systems, Inc. Electric modulation of sympathetic nervous system
US20080033511A1 (en) * 2002-03-22 2008-02-07 Leptos Biomedical, Inc. Dynamic nerve stimulation employing frequency modulation
US7551964B2 (en) 2002-03-22 2009-06-23 Leptos Biomedical, Inc. Splanchnic nerve stimulation for treatment of obesity
US7239912B2 (en) 2002-03-22 2007-07-03 Leptos Biomedical, Inc. Electric modulation of sympathetic nervous system
US7937145B2 (en) 2002-03-22 2011-05-03 Advanced Neuromodulation Systems, Inc. Dynamic nerve stimulation employing frequency modulation
US7937144B2 (en) 2002-03-22 2011-05-03 Advanced Neuromodulation Systems, Inc. Electric modulation of sympathetic nervous system
US20100249889A1 (en) * 2002-03-22 2010-09-30 Dobak Iii John D Neural Stimulation For Treatment of Metabolic Syndrome and Type 2 Diabetes
US20040230255A1 (en) * 2002-03-22 2004-11-18 Dobak John D. Splanchnic nerve stimulation for treatment of obesity
US20100234907A1 (en) * 2002-03-22 2010-09-16 Dobak Iii John D Splanchnic Nerve Stimulation for Treatment of Obesity
US20060190053A1 (en) * 2002-03-22 2006-08-24 Dobak John D Iii Neural stimulation for treatment of metabolic syndrome and type 2 diabetes
US20030181959A1 (en) * 2002-03-22 2003-09-25 Dobak John D. Wireless electric modulation of sympathetic nervous system
US7236822B2 (en) 2002-03-22 2007-06-26 Leptos Biomedical, Inc. Wireless electric modulation of sympathetic nervous system
US20090259279A1 (en) * 2002-03-22 2009-10-15 Dobak Iii John D Splanchnic nerve stimulation for treatment of obesity
US7702386B2 (en) 2002-03-22 2010-04-20 Leptos Biomedical, Inc. Nerve stimulation for treatment of obesity, metabolic syndrome, and Type 2 diabetes
US7689277B2 (en) 2002-03-22 2010-03-30 Leptos Biomedical, Inc. Neural stimulation for treatment of metabolic syndrome and type 2 diabetes
US8838231B2 (en) 2002-03-22 2014-09-16 Advanced Neuromodulation Systems, Inc. Neural Stimulation for treatment of metabolic syndrome and type 2 diabetes
US8145299B2 (en) 2002-03-22 2012-03-27 Advanced Neuromodulation Systems, Inc. Neural stimulation for treatment of metabolic syndrome and type 2 diabetes
US20030181958A1 (en) * 2002-03-22 2003-09-25 Dobak John D. Electric modulation of sympathetic nervous system
US20040053914A1 (en) * 2002-05-02 2004-03-18 Parviz Gharagozloo Therapeutic agents useful for treating pain
US6864261B2 (en) 2002-05-02 2005-03-08 Euro-Celtique S.A. Therapeutic agents useful for treating pain
US7799786B2 (en) 2002-06-28 2010-09-21 Purdue Pharma L.P. Therapeutic agents useful for treating pain
US7279493B2 (en) 2002-06-28 2007-10-09 Euro-Celtique S.A. Therapeutic agents useful for treating pain
US20080153835A1 (en) * 2002-06-28 2008-06-26 Euro-Celtique S.A. Therapeutic agents useful for treating pain
US20040106625A1 (en) * 2002-06-28 2004-06-03 Kyle Donald J. Therapeutic agents useful for treating pain
US7262194B2 (en) 2002-07-26 2007-08-28 Euro-Celtique S.A. Therapeutic agents useful for treating pain
US20040235853A1 (en) * 2002-07-26 2004-11-25 Kyle Donald J. Therapeutic agents useful for treating pain
US20080200472A1 (en) * 2002-07-26 2008-08-21 Euro-Celtique S.A. Therapeutic agents useful for treating pain
US7696207B2 (en) 2002-07-26 2010-04-13 Purdue Pharma L.P. Therapeutic agents useful for treating pain
US9393204B2 (en) 2002-07-31 2016-07-19 Ebi Life Sciences, Inc. Methods and compositions employing bicifadine for treating disability or functional impairment associated with acute pain, chronic pain, or neuropathic disorders
EP1396233A1 (en) 2002-09-06 2004-03-10 Biosense, Inc. Positioning system for neurological procedures in the brain
US20040049121A1 (en) * 2002-09-06 2004-03-11 Uri Yaron Positioning system for neurological procedures in the brain
US20050065575A1 (en) * 2002-09-13 2005-03-24 Dobak John D. Dynamic nerve stimulation for treatment of disorders
US7689276B2 (en) 2002-09-13 2010-03-30 Leptos Biomedical, Inc. Dynamic nerve stimulation for treatment of disorders
US20110082152A1 (en) * 2002-09-24 2011-04-07 Purdue Pharma L.P. Therapeutic agents useful for treating pain
US7157462B2 (en) 2002-09-24 2007-01-02 Euro-Celtique S.A. Therapeutic agents useful for treating pain
US20070142360A1 (en) * 2002-09-24 2007-06-21 Euro-Celtique S.A. Therapeutic agents useful for treating pain
US20040127501A1 (en) * 2002-09-24 2004-07-01 Zhengming Chen Therapeutic agents useful for treating pain
US20090042902A1 (en) * 2002-09-24 2009-02-12 Purdue Pharma L.P. Therapeutic agents useful for treating pain
US7855210B2 (en) 2002-09-24 2010-12-21 Purdue Pharma, L.P. Therapeutic agents useful for treating pain
US7737148B2 (en) 2002-09-24 2010-06-15 Purdue Pharma, L.P. Therapeutic agents useful for treating pain
US9434721B2 (en) 2002-12-24 2016-09-06 Purdue Pharma L.P. Therapeutic agents useful for treating pain
US20040186111A1 (en) * 2002-12-24 2004-09-23 Qun Sun Therapeutic agents useful for treating pain
US8536177B2 (en) 2002-12-24 2013-09-17 Purdue Pharma L.P. Therapeutic agents useful for treating pain
US8008300B2 (en) 2002-12-24 2011-08-30 Purdue Pharma L.P. Therapeutic agents useful for treating pain
US7582635B2 (en) 2002-12-24 2009-09-01 Purdue Pharma, L.P. Therapeutic agents useful for treating pain
US20100004254A1 (en) * 2002-12-24 2010-01-07 Purdue Pharma L.P. Therapeutic agents useful for treating pain
US8604037B2 (en) 2002-12-24 2013-12-10 Purdue Pharma, L.P. Therapeutic agents useful for treating pain
US8058292B2 (en) 2003-07-03 2011-11-15 Purdue Pharma L.P. Therapeutic agents useful for treating pain
US20100256111A1 (en) * 2003-07-03 2010-10-07 Purdue Pharma L.P. Therapeutic agents useful for treating pain
US7767699B2 (en) 2003-07-03 2010-08-03 Purdue Pharma, L.P. Therapeutic agents useful for treating pain
US20060235055A1 (en) * 2003-07-03 2006-10-19 Kyle Donald J Therapeutic agents useful for treating pain
US20050214217A1 (en) * 2004-03-26 2005-09-29 Mai Levite Methods of and pharmaceutical compositions for modulating T-lymphocyte adhesion, migration, gene expression and function by Glutamate and analogs thereof
US7747326B2 (en) * 2004-04-30 2010-06-29 Advanced Neuromodulation Systems, Inc. Method of treating mood disorders and/or anxiety disorders by brain stimulation
US20080125829A1 (en) * 2004-04-30 2008-05-29 Advanced Neuromodulation Systems, Inc. Method of treating mood disorders and/or anxiety disorders by brain stimulation
US11452871B2 (en) 2004-07-07 2022-09-27 Cleveland Clinic Foundation Method and device for displaying predicted volume of influence
US9760688B2 (en) 2004-07-07 2017-09-12 Cleveland Clinic Foundation Method and device for displaying predicted volume of influence
US10322285B2 (en) 2004-07-07 2019-06-18 Cleveland Clinic Foundation Method and device for displaying predicted volume of influence
US9770436B2 (en) 2004-08-18 2017-09-26 Euthymics Bioscience, Inc. Polymorphs of azabicyclohexane
US9139521B2 (en) 2004-08-18 2015-09-22 Euthymics Bioscience, Inc. Polymorphs of azabicyclohexane
US8765801B2 (en) 2004-08-18 2014-07-01 Euthymics Bioscience, Inc. Polymorphs of azabicyclohexane
US20060079943A1 (en) * 2004-08-31 2006-04-13 Narciso Hugh L Jr Devices and methods for gynecologic hormone modulation in mammals
US7623924B2 (en) 2004-08-31 2009-11-24 Leptos Biomedical, Inc. Devices and methods for gynecologic hormone modulation in mammals
US20080125831A1 (en) * 2004-09-14 2008-05-29 Neuropace, Inc. Responsive Therapy for Psychiatric Disorders
US7353065B2 (en) 2004-09-14 2008-04-01 Neuropace, Inc. Responsive therapy for psychiatric disorders
US20080125830A1 (en) * 2004-09-14 2008-05-29 Neuropace, Inc. Responsive Therapy for Psychiatric Disorders
US20060058856A1 (en) * 2004-09-14 2006-03-16 Neuropace, Inc. Responsive therapy for psychiatric disorders
US8463387B2 (en) 2004-10-21 2013-06-11 Advanced Neuromodulation Systems, Inc. Stimulation of the amygdalohippocampal complex to treat neurological conditions
US20100057160A1 (en) * 2004-10-21 2010-03-04 Advanced Neuromodulation Systems, Inc. Stimulation of the amygdalohippocampal complex to treat neurological conditions
US8239029B2 (en) * 2004-10-21 2012-08-07 Advanced Neuromodulation Systems, Inc. Stimulation of the amygdalohippocampal complex to treat neurological conditions
US20060100263A1 (en) * 2004-11-05 2006-05-11 Anthony Basile Antipyretic compositions and methods
US8700163B2 (en) 2005-03-04 2014-04-15 Cyberonics, Inc. Cranial nerve stimulation for treatment of substance addiction
US20070027482A1 (en) * 2005-07-27 2007-02-01 Cyberonics, Inc. Cranial nerve stimulation to treat a vocal cord disorder
US10039746B2 (en) 2005-07-27 2018-08-07 Otsuka America Pharmaceutical, Inc. 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders
US9205074B2 (en) 2005-07-27 2015-12-08 Neurovance, Inc. 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders
US20090233978A1 (en) * 2005-07-27 2009-09-17 Phil Skolnick Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders
US8877798B2 (en) 2005-07-27 2014-11-04 Neurovance, Inc. 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders
US7840280B2 (en) 2005-07-27 2010-11-23 Cyberonics, Inc. Cranial nerve stimulation to treat a vocal cord disorder
US9737506B2 (en) 2005-07-27 2017-08-22 Neurovance, Inc. 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders
US7706874B2 (en) 2005-07-28 2010-04-27 Cyberonics, Inc. Stimulating cranial nerve to treat disorders associated with the thyroid gland
US8660647B2 (en) 2005-07-28 2014-02-25 Cyberonics, Inc. Stimulating cranial nerve to treat pulmonary disorder
US20070027498A1 (en) * 2005-07-29 2007-02-01 Cyberonics, Inc. Selective nerve stimulation for the treatment of eating disorders
US20070027499A1 (en) * 2005-07-29 2007-02-01 Cyberonics, Inc. Neurostimulation device for treating mood disorders
US7499752B2 (en) 2005-07-29 2009-03-03 Cyberonics, Inc. Selective nerve stimulation for the treatment of eating disorders
US20070043100A1 (en) * 2005-08-16 2007-02-22 Hagen Eric J Novel polymorphs of azabicyclohexane
US20090326245A1 (en) * 2005-08-16 2009-12-31 Hagen Eric J Novel Polymorphs of Azabicyclohexane
US20070225773A1 (en) * 2005-09-28 2007-09-27 Yang Shen Implantable transcranial pulse generator having a collapsible portion
US7555344B2 (en) 2005-10-28 2009-06-30 Cyberonics, Inc. Selective neurostimulation for treating epilepsy
US10360511B2 (en) 2005-11-28 2019-07-23 The Cleveland Clinic Foundation System and method to estimate region of tissue activation
US8725243B2 (en) 2005-12-28 2014-05-13 Cyberonics, Inc. Methods and systems for recommending an appropriate pharmacological treatment to a patient for managing epilepsy and other neurological disorders
US9592004B2 (en) 2005-12-28 2017-03-14 Cyberonics, Inc. Methods and systems for managing epilepsy and other neurological disorders
US8868172B2 (en) 2005-12-28 2014-10-21 Cyberonics, Inc. Methods and systems for recommending an appropriate action to a patient for managing epilepsy and other neurological disorders
US9044188B2 (en) 2005-12-28 2015-06-02 Cyberonics, Inc. Methods and systems for managing epilepsy and other neurological disorders
US7657310B2 (en) 2006-01-26 2010-02-02 Cyberonics, Inc. Treatment of reproductive endocrine disorders by vagus nerve stimulation
US7801601B2 (en) 2006-01-27 2010-09-21 Cyberonics, Inc. Controlling neuromodulation using stimulus modalities
US20080045725A1 (en) * 2006-04-28 2008-02-21 Murry Jerry A Process For The Synthesis of (+) And (-)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane
US9527813B2 (en) 2006-04-28 2016-12-27 Euthymics Bioscience, Inc. Process for the synthesis of (+) and (−)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane
US8295926B2 (en) 2006-06-02 2012-10-23 Advanced Neuromodulation Systems, Inc. Dynamic nerve stimulation in combination with other eating disorder treatment modalities
US9480845B2 (en) 2006-06-23 2016-11-01 Cyberonics, Inc. Nerve stimulation device with a wearable loop antenna
US7676263B2 (en) 2006-06-23 2010-03-09 Neurovista Corporation Minimally invasive system for selecting patient-specific therapy parameters
US20110171325A1 (en) * 2006-08-30 2011-07-14 Andres Lozano Systems and Methods for Treating Pain Using Brain Stimulation
US8412337B2 (en) 2006-08-30 2013-04-02 Functional Neuroscience, Inc. Systems and methods for treating pain using brain stimulation
US8116877B2 (en) 2006-08-30 2012-02-14 Functional Neuroscience, Inc. Systems and methods for treating pain using brain stimulation
US20080269348A1 (en) * 2006-11-07 2008-10-30 Phil Skolnick Novel Arylbicyclo[3.1.0]Hexylamines And Methods And Compositions For Their Preparation And Use
US20080293822A1 (en) * 2006-11-07 2008-11-27 Phil Skolnick Novel Arylbicyclo[3.1.0]Hexylamines And Methods And Compositions For Their Preparation And Use
US8138377B2 (en) 2006-11-07 2012-03-20 Dov Pharmaceutical, Inc. Arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use
US8855775B2 (en) 2006-11-14 2014-10-07 Cyberonics, Inc. Systems and methods of reducing artifact in neurological stimulation systems
US8295934B2 (en) 2006-11-14 2012-10-23 Neurovista Corporation Systems and methods of reducing artifact in neurological stimulation systems
US7706875B2 (en) 2007-01-25 2010-04-27 Cyberonics, Inc. Modulation of drug effects by vagus nerve stimulation
US9622675B2 (en) 2007-01-25 2017-04-18 Cyberonics, Inc. Communication error alerting in an epilepsy monitoring system
US9898656B2 (en) 2007-01-25 2018-02-20 Cyberonics, Inc. Systems and methods for identifying a contra-ictal condition in a subject
US8543199B2 (en) 2007-03-21 2013-09-24 Cyberonics, Inc. Implantable systems and methods for identifying a contra-ictal condition in a subject
US9445730B2 (en) 2007-03-21 2016-09-20 Cyberonics, Inc. Implantable systems and methods for identifying a contra-ictal condition in a subject
US8036736B2 (en) 2007-03-21 2011-10-11 Neuro Vista Corporation Implantable systems and methods for identifying a contra-ictal condition in a subject
US20090069374A1 (en) * 2007-06-06 2009-03-12 Phil Skolnick Novel 1-Heteroaryl-3-Azabicyclo[3.1.0]Hexanes, Methods For Their Preparation And Their Use As Medicaments
US9597315B2 (en) 2007-06-06 2017-03-21 Euthymics Bioscience, Inc. 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
US9133159B2 (en) 2007-06-06 2015-09-15 Neurovance, Inc. 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
US9788744B2 (en) 2007-07-27 2017-10-17 Cyberonics, Inc. Systems for monitoring brain activity and patient advisory device
US20090118777A1 (en) * 2007-08-09 2009-05-07 Kobi Iki Efferent and afferent splanchnic nerve stimulation
US20090129856A1 (en) * 2007-11-21 2009-05-21 Michael Gomez Quick-release system
US11406317B2 (en) 2007-12-28 2022-08-09 Livanova Usa, Inc. Method for detecting neurological and clinical manifestations of a seizure
US9259591B2 (en) 2007-12-28 2016-02-16 Cyberonics, Inc. Housing for an implantable medical device
US10434302B2 (en) 2008-02-11 2019-10-08 Intelect Medical, Inc. Directional electrode devices with locating features
US9545510B2 (en) 2008-02-12 2017-01-17 Intelect Medical, Inc. Directional lead assembly with electrode anchoring prongs
US9526902B2 (en) 2008-05-15 2016-12-27 Boston Scientific Neuromodulation Corporation VOA generation system and method using a fiber specific analysis
US8788042B2 (en) 2008-07-30 2014-07-22 Ecole Polytechnique Federale De Lausanne (Epfl) Apparatus and method for optimized stimulation of a neurological target
US10952627B2 (en) 2008-07-30 2021-03-23 Ecole Polytechnique Federale De Lausanne Apparatus and method for optimized stimulation of a neurological target
US10166392B2 (en) 2008-07-30 2019-01-01 Ecole Polytechnique Federale De Lausanne Apparatus and method for optimized stimulation of a neurological target
US9072906B2 (en) 2008-07-30 2015-07-07 Ecole Polytechnique Federale De Lausanne Apparatus and method for optimized stimulation of a neurological target
US11123548B2 (en) 2008-11-12 2021-09-21 Ecole Polytechnique Federale De Lausanne Microfabricated neurostimulation device
US10406350B2 (en) 2008-11-12 2019-09-10 Ecole Polytechnique Federale De Lausanne Microfabricated neurostimulation device
US9440082B2 (en) 2008-11-12 2016-09-13 Ecole Polytechnique Federale De Lausanne Microfabricated neurostimulation device
US8788064B2 (en) 2008-11-12 2014-07-22 Ecole Polytechnique Federale De Lausanne Microfabricated neurostimulation device
US8849390B2 (en) 2008-12-29 2014-09-30 Cyberonics, Inc. Processing for multi-channel signals
US8588933B2 (en) 2009-01-09 2013-11-19 Cyberonics, Inc. Medical lead termination sleeve for implantable medical devices
US9289595B2 (en) 2009-01-09 2016-03-22 Cyberonics, Inc. Medical lead termination sleeve for implantable medical devices
US20100268297A1 (en) * 2009-02-24 2010-10-21 Hans Neisz Duodenal Stimulation To Induce Satiety
US8321030B2 (en) 2009-04-20 2012-11-27 Advanced Neuromodulation Systems, Inc. Esophageal activity modulated obesity therapy
US8340772B2 (en) 2009-05-08 2012-12-25 Advanced Neuromodulation Systems, Inc. Brown adipose tissue utilization through neuromodulation
US8786624B2 (en) 2009-06-02 2014-07-22 Cyberonics, Inc. Processing for multi-channel signals
US10981013B2 (en) 2009-08-27 2021-04-20 The Cleveland Clinic Foundation System and method to estimate region of tissue activation
US11944821B2 (en) 2009-08-27 2024-04-02 The Cleveland Clinic Foundation System and method to estimate region of tissue activation
US9604055B2 (en) 2009-12-01 2017-03-28 Ecole Polytechnique Federale De Lausanne Microfabricated surface neurostimulation device and methods of making and using the same
US9192767B2 (en) 2009-12-01 2015-11-24 Ecole Polytechnique Federale De Lausanne Microfabricated surface neurostimulation device and methods of making and using the same
US8774937B2 (en) 2009-12-01 2014-07-08 Ecole Polytechnique Federale De Lausanne Microfabricated surface neurostimulation device and methods of making and using the same
US9776003B2 (en) 2009-12-02 2017-10-03 The Cleveland Clinic Foundation Reversing cognitive-motor impairments in patients having a neuro-degenerative disease using a computational modeling approach to deep brain stimulation programming
US9643019B2 (en) 2010-02-12 2017-05-09 Cyberonics, Inc. Neurological monitoring and alerts
US9549708B2 (en) 2010-04-01 2017-01-24 Ecole Polytechnique Federale De Lausanne Device for interacting with neurological tissue and methods of making and using the same
US11766560B2 (en) 2010-04-01 2023-09-26 Ecole Polytechnique Federale De Lausanne Device for interacting with neurological tissue and methods of making and using the same
US9867989B2 (en) 2010-06-14 2018-01-16 Boston Scientific Neuromodulation Corporation Programming interface for spinal cord neuromodulation
US11717210B2 (en) 2010-09-28 2023-08-08 Masimo Corporation Depth of consciousness monitor including oximeter
US9538949B2 (en) 2010-09-28 2017-01-10 Masimo Corporation Depth of consciousness monitor including oximeter
US10531811B2 (en) 2010-09-28 2020-01-14 Masimo Corporation Depth of consciousness monitor including oximeter
US9501829B2 (en) 2011-03-29 2016-11-22 Boston Scientific Neuromodulation Corporation System and method for atlas registration
US9592389B2 (en) 2011-05-27 2017-03-14 Boston Scientific Neuromodulation Corporation Visualization of relevant stimulation leadwire electrodes relative to selected stimulation information
US12042481B2 (en) 2011-07-30 2024-07-23 Otsuka America Pharmaceutical, Inc. Use of (1R,5S)-(+)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane in the treatment of conditions affected by monoamine neurotransmitters
US9925382B2 (en) 2011-08-09 2018-03-27 Boston Scientific Neuromodulation Corporation Systems and methods for stimulation-related volume analysis, creation, and sharing
US9604067B2 (en) 2012-08-04 2017-03-28 Boston Scientific Neuromodulation Corporation Techniques and methods for storing and transferring registration, atlas, and lead information between medical devices
US9561380B2 (en) 2012-08-28 2017-02-07 Boston Scientific Neuromodulation Corporation Point-and-click programming for deep brain stimulation using real-time monopolar review trendlines
US10946201B2 (en) 2012-08-28 2021-03-16 Boston Scientific Neuromodulation Corporation Point-and-click programming for deep brain stimulation using real-time monopolar review trendlines
US10016610B2 (en) 2012-08-28 2018-07-10 Boston Scientific Neuromodulation Corporation Point-and-click programming for deep brain stimulation using real-time monopolar review trendlines
US11938328B2 (en) 2012-08-28 2024-03-26 Boston Scientific Neuromodulation Corporation Point-and-click programming for deep brain stimulation using real-time monopolar review trendlines
US11633608B2 (en) 2012-08-28 2023-04-25 Boston Scientific Neuromodulation Corporation Point-and-click programming for deep brain stimulation using real-time monopolar review trendlines
US9821167B2 (en) 2012-08-28 2017-11-21 Boston Scientific Neuromodulation Corporation Point-and-click programming for deep brain stimulation using real-time monopolar review trendlines
US10265532B2 (en) 2012-08-28 2019-04-23 Boston Scientific Neuromodulation Corporation Point-and-click programming for deep brain stimulation using real-time monopolar review trendlines
US12144995B2 (en) 2012-08-28 2024-11-19 Boston Scientific Neuromodulation Corporation Point-and-click programming for deep brain stimulation using real-time monopolar review trendlines
US9643017B2 (en) 2012-08-28 2017-05-09 Boston Scientific Neuromodulation Corporation Capture and visualization of clinical effects data in relation to a lead and/or locus of stimulation
US9792412B2 (en) 2012-11-01 2017-10-17 Boston Scientific Neuromodulation Corporation Systems and methods for VOA model generation and use
US11923093B2 (en) 2012-11-01 2024-03-05 Boston Scientific Neuromodulation Corporation Systems and methods for VOA model generation and use
US9959940B2 (en) 2012-11-01 2018-05-01 Boston Scientific Neuromodulation Corporation Systems and methods for VOA model generation and use
US10966620B2 (en) 2014-05-16 2021-04-06 Aleva Neurotherapeutics Sa Device for interacting with neurological tissue and methods of making and using the same
US11311718B2 (en) 2014-05-16 2022-04-26 Aleva Neurotherapeutics Sa Device for interacting with neurological tissue and methods of making and using the same
EP3151913A4 (en) * 2014-06-03 2017-11-15 Ridder, Dirk, De Systems and methods of treating a neurological disorder in a patient
AU2015271702B2 (en) * 2014-06-03 2020-02-06 Dirk De Ridder Systems and methods of treating a neurological disorder in a patient
US9959388B2 (en) 2014-07-24 2018-05-01 Boston Scientific Neuromodulation Corporation Systems, devices, and methods for providing electrical stimulation therapy feedback
US10272247B2 (en) 2014-07-30 2019-04-30 Boston Scientific Neuromodulation Corporation Systems and methods for stimulation-related volume analysis, creation, and sharing with integrated surgical planning and stimulation programming
US10265528B2 (en) 2014-07-30 2019-04-23 Boston Scientific Neuromodulation Corporation Systems and methods for electrical stimulation-related patient population volume analysis and use
US11806534B2 (en) 2014-07-30 2023-11-07 Boston Scientific Neuromodulation Corporation Systems and methods for stimulation-related biological circuit element analysis and use
US11602635B2 (en) 2014-07-30 2023-03-14 Boston Scientific Neuromodulation Corporation Systems and methods for stimulation-related volume analysis of therapeutic effects and other clinical indications
US9889304B2 (en) 2014-08-27 2018-02-13 Aleva Neurotherapeutics Leadless neurostimulator
US9403011B2 (en) 2014-08-27 2016-08-02 Aleva Neurotherapeutics Leadless neurostimulator
US11730953B2 (en) 2014-08-27 2023-08-22 Aleva Neurotherapeutics Deep brain stimulation lead
US9474894B2 (en) 2014-08-27 2016-10-25 Aleva Neurotherapeutics Deep brain stimulation lead
US11167126B2 (en) 2014-08-27 2021-11-09 Aleva Neurotherapeutics Deep brain stimulation lead
US9572985B2 (en) 2014-08-27 2017-02-21 Aleva Neurotherapeutics Method of manufacturing a thin film leadless neurostimulator
US9925376B2 (en) 2014-08-27 2018-03-27 Aleva Neurotherapeutics Treatment of autoimmune diseases with deep brain stimulation
US10441779B2 (en) 2014-08-27 2019-10-15 Aleva Neurotherapeutics Deep brain stimulation lead
US10201707B2 (en) 2014-08-27 2019-02-12 Aleva Neurotherapeutics Treatment of autoimmune diseases with deep brain stimulation
US10065031B2 (en) 2014-08-27 2018-09-04 Aleva Neurotherapeutics Deep brain stimulation lead
US10154815B2 (en) 2014-10-07 2018-12-18 Masimo Corporation Modular physiological sensors
US12208268B2 (en) 2014-10-07 2025-01-28 Boston Scientific Neuromodulation Corporation Systems, devices, and methods for electrical stimulation using feedback to adjust stimulation parameters
US9974959B2 (en) 2014-10-07 2018-05-22 Boston Scientific Neuromodulation Corporation Systems, devices, and methods for electrical stimulation using feedback to adjust stimulation parameters
US10357657B2 (en) 2014-10-07 2019-07-23 Boston Scientific Neuromodulation Corporation Systems, devices, and methods for electrical stimulation using feedback to adjust stimulation parameters
US11717218B2 (en) 2014-10-07 2023-08-08 Masimo Corporation Modular physiological sensor
US11202913B2 (en) 2014-10-07 2021-12-21 Boston Scientific Neuromodulation Corporation Systems, devices, and methods for electrical stimulation using feedback to adjust stimulation parameters
US10765367B2 (en) 2014-10-07 2020-09-08 Masimo Corporation Modular physiological sensors
US10780283B2 (en) 2015-05-26 2020-09-22 Boston Scientific Neuromodulation Corporation Systems and methods for analyzing electrical stimulation and selecting or manipulating volumes of activation
US9956419B2 (en) 2015-05-26 2018-05-01 Boston Scientific Neuromodulation Corporation Systems and methods for analyzing electrical stimulation and selecting or manipulating volumes of activation
US11160981B2 (en) 2015-06-29 2021-11-02 Boston Scientific Neuromodulation Corporation Systems and methods for selecting stimulation parameters based on stimulation target region, effects, or side effects
US11110280B2 (en) 2015-06-29 2021-09-07 Boston Scientific Neuromodulation Corporation Systems and methods for selecting stimulation parameters by targeting and steering
US10441800B2 (en) 2015-06-29 2019-10-15 Boston Scientific Neuromodulation Corporation Systems and methods for selecting stimulation parameters by targeting and steering
WO2017044967A1 (en) * 2015-09-11 2017-03-16 Taca Jr Dr Arturo C Treatment of addiction and dependency
US10071249B2 (en) 2015-10-09 2018-09-11 Boston Scientific Neuromodulation Corporation System and methods for clinical effects mapping for directional stimulation leads
US10716942B2 (en) 2016-04-25 2020-07-21 Boston Scientific Neuromodulation Corporation System and methods for directional steering of electrical stimulation
US10776456B2 (en) 2016-06-24 2020-09-15 Boston Scientific Neuromodulation Corporation Systems and methods for visual analytics of clinical effects
US10350404B2 (en) 2016-09-02 2019-07-16 Boston Scientific Neuromodulation Corporation Systems and methods for visualizing and directing stimulation of neural elements
US10780282B2 (en) 2016-09-20 2020-09-22 Boston Scientific Neuromodulation Corporation Systems and methods for steering electrical stimulation of patient tissue and determining stimulation parameters
US11752348B2 (en) 2016-10-14 2023-09-12 Boston Scientific Neuromodulation Corporation Systems and methods for closed-loop determination of stimulation parameter settings for an electrical simulation system
US10603498B2 (en) 2016-10-14 2020-03-31 Boston Scientific Neuromodulation Corporation Systems and methods for closed-loop determination of stimulation parameter settings for an electrical simulation system
US10792501B2 (en) 2017-01-03 2020-10-06 Boston Scientific Neuromodulation Corporation Systems and methods for selecting MRI-compatible stimulation parameters
US10589104B2 (en) 2017-01-10 2020-03-17 Boston Scientific Neuromodulation Corporation Systems and methods for creating stimulation programs based on user-defined areas or volumes
US10625082B2 (en) 2017-03-15 2020-04-21 Boston Scientific Neuromodulation Corporation Visualization of deep brain stimulation efficacy
US11357986B2 (en) 2017-04-03 2022-06-14 Boston Scientific Neuromodulation Corporation Systems and methods for estimating a volume of activation using a compressed database of threshold values
US10716505B2 (en) 2017-07-14 2020-07-21 Boston Scientific Neuromodulation Corporation Systems and methods for estimating clinical effects of electrical stimulation
US10960214B2 (en) 2017-08-15 2021-03-30 Boston Scientific Neuromodulation Corporation Systems and methods for controlling electrical stimulation using multiple stimulation fields
US11738192B2 (en) 2018-03-02 2023-08-29 Aleva Neurotherapeutics Neurostimulation device
US11266830B2 (en) 2018-03-02 2022-03-08 Aleva Neurotherapeutics Neurostimulation device
US11583684B2 (en) 2018-04-27 2023-02-21 Boston Scientific Neuromodulation Corporation Systems and methods for visualizing and programming electrical stimulation
US11298553B2 (en) 2018-04-27 2022-04-12 Boston Scientific Neuromodulation Corporation Multi-mode electrical stimulation systems and methods of making and using
US11944823B2 (en) 2018-04-27 2024-04-02 Boston Scientific Neuromodulation Corporation Multi-mode electrical stimulation systems and methods of making and using
US11285329B2 (en) 2018-04-27 2022-03-29 Boston Scientific Neuromodulation Corporation Systems and methods for visualizing and programming electrical stimulation
US12403315B2 (en) 2021-04-27 2025-09-02 Boston Scientific Neuromodulation Corporation Systems and methods for automated programming of electrical stimulation
US12403313B2 (en) 2021-06-15 2025-09-02 Boston Scientific Neuromodulation Corporation Methods and systems for estimating neural activation by stimulation using a stimulation system

Similar Documents

Publication Publication Date Title
US6109269A (en) Method of treating addiction by brain infusion
US5975085A (en) Method of treating schizophrenia by brain stimulation and drug infusion
US6176242B1 (en) Method of treating manic depression by brain infusion
US6227203B1 (en) Techniques for controlling abnormal involuntary movements by brain stimulation and drug infusion
US6128537A (en) Techniques for treating anxiety by brain stimulation and drug infusion
US6094598A (en) Method of treating movement disorders by brain stimulation and drug infusion
US5713923A (en) Techniques for treating epilepsy by brain stimulation and drug infusion
US5782798A (en) Techniques for treating eating disorders by brain stimulation and drug infusion
US6356784B1 (en) Method of treating movement disorders by electrical stimulation and/or drug infusion of the pendunulopontine nucleus
US5735814A (en) Techniques of treating neurodegenerative disorders by brain infusion
US6353762B1 (en) Techniques for selective activation of neurons in the brain, spinal cord parenchyma or peripheral nerve
US7151961B1 (en) Treatment of movement disorders by brain stimulation
EP1014881B1 (en) System for treating neurodegenerative disorders by infusion of nerve growth factors into the brain
US6832114B1 (en) Systems and methods for modulation of pancreatic endocrine secretion and treatment of diabetes
EP3180080B1 (en) Brain stimulation system including multiple stimulation modes
US6356788B2 (en) Apparatus and method for adjunct (add-on) therapy for depression, migraine, neuropsychiatric disorders, partial complex epilepsy, generalized epilepsy and involuntary movement disorders utilizing an external stimulator
US5683422A (en) Method and apparatus for treating neurodegenerative disorders by electrical brain stimulation
US8467879B1 (en) Treatment of pain by brain stimulation
US8380304B2 (en) Regulation of neurotrophins
US9352145B2 (en) Methods and systems for treating a psychotic disorder
US20040015202A1 (en) Combination epidural infusion/stimulation method and system
JP2005516684A (en) Micro injection device
US9095713B2 (en) Methods and systems for treating autism by decreasing neural activity within the brain
US9358393B1 (en) Stimulation methods and systems for treating an auditory dysfunction
US20220134076A1 (en) Implantable medical device for delivery of pharmacological agents to the deep brain structures

Legal Events

Date Code Title Description
AS Assignment

Owner name: MEDTRONIC, INC, MINNESOTA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:RISE, MARK T.;GRAVES, NINA;REEL/FRAME:009931/0513

Effective date: 19990430

STCF Information on status: patent grant

Free format text: PATENTED CASE

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

CC Certificate of correction
FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

FPAY Fee payment

Year of fee payment: 12